1

PORPP

D E P A R T M E N T O F P H A R M A C Y

U N I V E R S I T Y O F WA S H I N G T O N

‒P

harm

aceu

tica

l Ou

tcom

es R

esea

rch

and

Polic

y P

rogr

am

B I E N N I A L R E P O R T

2

C o n te n t sF R O M T H E D I R E C T O R 3

F R O M T H E D E A N 4

F R O M T H E D E PA R T M E N T C H A I R 4

P E O P L E & P R O G R A M S 5

O U R P R O G R A M & O U R M I S S I O N 6

A C A D E M I C P R O G R A M S 7

F A C U LT Y & S TA F F P R O F I L E S 8

F A C U LT Y F O C U S : T H O M A S H A Z L E T 11

O U R S T U D E N T S & F E L L OW S 12

H O N O R S & A WA R D S 14

R E S E A R C H P R O G R A M S & G R A N T S 16

A C A D E M I C & C O M M U N I T Y I N T E R FAC E 18

F A C U LT Y A C T I V I T I E S & S E R V I C E 19

C O R P O R AT E A D V I S O RY B OA R D 21

C O N F E R E N C E S & S Y M P O S I A 22

F A C U LT Y F O C U S : S E A N S U L L I VA N 23

G R A N D R O U N D S S E M I N A R S E R I E S 24

O U R P R E S E N T ; O U R F U T U R E 25

N E W F A C U LT Y 26

F A C U LT Y F O C U S : D AV I D V E E N S T R A 27

N E W A LU M N I 28

V I S I T I N G S C H O L A R S 30

G R A D UAT E P R O G R A M R E V I E W 30

G R A D UAT E E M P L OY M E N T 31

S E L E C T E D P U B L I C AT I O N S 32

G R A N T S , G I F T S , & A F F I L I AT I O N S 35

3

I AM PLEASED TO PROVIDE YOU with the biennial report of

the University of Washington Pharmaceutical Outcomes Research and

Policy Program (PORPP). This report catalogues the activities,

scholarship, and professional accomplishments of our faculty and

graduate students during 2000–2002. As you will see while you turn

the pages, these dedicated and hard working individuals have made

substantial achievements in their respective disciplines, too numerous

to list in this brief introduction. PORPP is extremely fortunate to have

scientists and students of the highest caliber.

Three organizational activities are worth noting. In the summer of

2001, Dr. Beth Devine joined us to serve as Associate Director. With

the expansion of graduate and educational activities, PORPP will

benefit from the additional support Dr. Devine can provide.

The PORPP graduate program underwent external review from peer

academic colleagues in 2001 at the request of the Dean of the Graduate

School. This is a standard procedure for University of Washington

departments and programs that offer graduate degrees. We received

very high marks for the PhD program and were granted a 10-year

accreditation by the Graduate School. Furthermore, we were asked to

consider expanding enrollment in the graduate program.

Also in 2001, we invited eleven colleagues, representing the pharma-

ceutical and managed care industry, to convene an external advisory

board. The board, chaired by Dr. Edward Bortnichak of Sanofi-

Synthelabo, met in November with the specific objective of giving

input on the content, direction, and quality of our graduate and

research programs as they relate to industrial needs. The outcome was

a focused list of recommendations to further enhance our program

offerings. We have begun to take up some of these recommendations

internally.

Finally, I would like to acknowledge the dedicated support from our

staff program coordinators, Penny Evans and Cindy Bush, who have

played a major role in the accomplishments that you see highlighted

throughout these pages.

—Sean Sullivan, Director

From the Director

4

AS YOU READ THIS BIENNIAL REPORT of the Pharmaceutical

Outcomes Research and Policy Program (PORPP), I am sure that you will

agree that in its few short years of existence PORPP has been one of the

outstanding success stories in our School of Pharmacy. From its inception in

1995 by Dr. Andy Stergachis, through its maturation under the masterful

guidance of its director, Dr. Sean Sullivan, PORPP has met its primary goal of

advancing the health of the public through improving decision-making

regarding pharmaceutical therapy and policy. Attesting to this achievement

are the many awards and honors bestowed on PORPP faculty and students for

their work, and the large number of news stories that have highlighted the

work. Furthermore, our advisory boards are insistent that we need to grow the

program to meet the demands of a society that wants improved health care at

a reasonable cost. As Irving Berlin once said, “The toughest thing about

success is that you’ve got to keep on being a success.” I am convinced that

PORPP will do just that, and am genuinely excited about its future.

—Sid Nelson, Dean, School of Pharmacy

From the Dean“Nothing succeeds like success.” Alexandre Dumas

From the Department ChairIT IS WITH GREAT PLEASURE that I offer my remarks to the 2000-2002

Biennial Report for PORPP. This report shows the continual growth and

success of the Program in many respects. During this period, the faculty has

expanded with the addition of several research, adjunct, and affiliate appoint-

ments (Drs. Devine, Patrick and Smith). The graduate program celebrated the

graduation of the first two classes of PhD students, and the first from the

combined PharmD-MS program. PORPP continues to expand the scope of its

research, education, and service activities. The tremendous success and

impact of the recent conferences and workshops sponsored by PORPP are

impressive. The research accomplishments of the faculty and their graduate

students have been repeatedly recognized by a number of national and

international scientific societies and professional organizations. The success

of PORPP is truly a distinction for the Department of Pharmacy and the

School as a whole. I congratulate the PORPP faculty for their accomplish-

ments, particularly in view of the relatively short history of the Program and

serious constraint in resources that this University has faced in the past.

I also want to take this opportunity to express my sincere appreciation to the

many colleagues in the academic and research communities, professional

organizations, and healthcare and drug industries for their continual support,

both in financial terms and collaborative opportunities.

—Danny Shen, Chair, Department of Pharmacy

55

PORPP

5

O U R P R O G R A M ; O U R M I S S I O N

A C A D E M I C P R O G R A M S

FA C U LT Y & STA F F PRO F I L E S

FA C U LT Y FO C U S: TH O M A S HA Z L E T

OU R ST U D E N TS & FE L L OWS

HO N O R S & A WA R D S

R E S E A R C H P R O G R A M S & G R A N T S

graduation 2001

(l to r):

Drs. Eric Johnson,

Sean Sullivan,

Todd Lee,

Mitch Higashi,

David Veenstra,

Nathorn

Chaiyakunapruk,

Tom Hazlet,

Holly Trautman, and

Jackie Gardner

Pha

rmac

euti

cal O

utc

omes

Res

earc

h an

d Po

licy

Pro

gram P E O P L E & P R O G R A M S

6

Our ProgramThe University of Washington (UW)

Department of Pharmacy created the

Pharmaceutical Outcomes Research and

Policy Program (PORPP) in 1995 with the

goal of advancing the health of the public

through improving decision-making in

regard to pharmaceutical therapy and

policy. Since that time, PORPP has helped

the UW become a nationally recognized

center for research in pharmaco-

epidemiology, pharmacoeconomics, and

pharmaceutical policy research. Recently,

PORPP has expanded its academic and

research programs and its mission to

include five related areas.

Our Mission■ Conduct research on the effects and uses of

pharmaceuticals in human populations.

■ Provide graduate and postgraduate training in

pharmaceutical outcomes research and policy.

■ Disseminate timely information regarding

pharmaceutical outcomes research and policies

to government, the pharmaceutical industry,

health care providers, and the general public.

■ Inform, through research and scholarship,

regional and national policies governing

pharmaceuticals and pharmaceutical services.

■ Be considered a resource for industry research,consultation, and training partnerships.

6

(l to r):

Dean Sid Nelson and

Dr. Phil Hansten

(Departmment of

Pharmacy)

at Graduation 2001

7

PhD in Pharmaceutical SciencesPharmaceutical outcomes research uses research

methods from a variety of disciplines, including

biostatistics, economics, and epidemiology to

evaluate clinical outcomes, morbidity, quality of

life, and cost-effectiveness. In the PhD program,

students are trained in economic evaluation,

pharmacoepidemiology, health services research,

outcomes assessment, and pharmaceutical policy

formulation and evaluation. The PhD in Pharma-

ceutical Sciences prepares students for career

opportunities in:■ Teaching and research at colleges and

universities.■ Safety and economic evaluation of products

in the pharmaceutical, biotechnology and

medical device industries.■ Policy analysis for professional associations,

health care insurance providers, and govern-

mental agencies.■ Management within hospitals, managed care

organizations, and programs concerned with

reimbursement for pharmaceuticals and other

medical technologies.

Concurrent Doctor of Pharmacy& Master’s DegreeThe combined Doctor of Pharmacy–Master’s

(PharmD–MS) Program in Pharmaceutical

Outcomes Research and Policy is targeted toward

outstanding students currently enrolled in the UW

School of Pharmacy’s Doctor of Pharmacy

program who have a proven interest in the field of

Outcomes Research and Policy. The concurrent

Academic Programs

The Department of Pharmacy offers two graduate degree options in its Pharmaceutical

Outcomes Research and Policy Program (PORPP): a PhD in Pharmaceutical Sciences,

and a combined Doctor of Pharmacy–Master of Science. The Program is enhanced by

several fellowship opportunities.

degree program allows these students to complete

both degrees within five years. Students complete

extensive graduate coursework and at least ten

credits of practicum and research training in a

managed care, government, industry, or other

appropriate setting. The program offers efficient

and specialized training in pharmaceutical

outcomes, through research experience and

didactic learning.

The demand for clinically trained students

with outcomes research capabilities is high in the

pharmaceutical, medical device, and managed

care industries, and will continue to grow. The

PharmD–MS program was created to meet this

demand.

FellowshipsPORPP is enhanced by a variety of fellowship

programs, including pre- and postdoctoral

fellowships, post-PharmD fellowships, and

managed care fellowships. Fellowships are

sponsored by foundations and the pharmaceutical

industry. During 2000–2002, the following

fellowships enabled students to reach their

academic goals:

■ American Foundation for Pharmaceutical

Education.■ AstraZeneca Managed Care Fellowship.■ Achievement Rewards for College Scientists.■ Blood Systems Foundation.■ Magnuson Scholar Award.■ Pharmaceutical Research and Manufacturers

of America Foundation.■ Roche Global Health Economics.

PhD, PharmD-MS, Fellowships

The demand for

clinically trained

students with

outcomes research

capabilities is high

in the pharma-

ceutical, medical

device, and

managed care

industries, and will

continue to grow

8

Science, and was elected to the Institute

of Medicine of the National Academy of

Science. In 1976, he was honored with the

Academy of Pharmaceutical Sciences

Research Achievement Award for Stimula-

tion of Research, and in 1980, he was

elected Honorary President of the Australia/

New Zealand Association for the Advance-

ment of Science, Pharmaceutical Sciences

Section. He is a consultant to FDA’s Center

for Drug Evaluation and Research, the

Veterans’ Administration Department of

Medicine and Surgery, and pharmaceutical

firms, including GlaxoSmithKline and

Roche. He is the author of nearly 200

articles and book chapters, has published

four books, and is the editor of the PORPP

Report and scientific editor of Pharmaco-

therapy. Dr. Gibaldi earned his BC from

Columbia College of Pharmacy and his

PhD from Columbia University.

Thomas K. Hazlet, PharmD, DrPHAssociate ProfessorDr. Hazlet completed a doctorate in

Pharmacy at the University of California

(UC), San Francisco and a residency in

hospital pharmacy at Yale-New Haven

Hospital. He earned a doctorate in Public

Health in the Health Policy and Adminis-

tration Program at UC Berkeley. His

background includes experience in

industrial microbiology with Baxter

Healthcare Corporation, parenteral

nutrition at UCLA Medical Center,

pharmacy practice in a community

hospital, as a Food and Drug Scientist

with the California Department of Health

Services’ Food and Drug Branch, and as

a member of the FDA’s Pacific Region

Biotechnology Team. His regulatory

activities include reviewing investigational

new drug applications and acting as a

technical liaison with field investigator staff,

clinical sponsors, industry representatives,

and legislators. Dr. Hazlet’s research is

directed toward assessing the consequences

of pharmaceuticals policy change and

teaching, research, serviceFaculty & Staff Profiles

FacultyDavid K. Blough, PhDClinical Associate ProfessorDr. Blough earned his PhD in Statistics

at Iowa State University. He has served

as collaborating statistician on numerous

research projects within the department,

including research on asthma, risk of

seizures associated with tramadol, adverse

drug reactions in the elderly, and the

evaluation of reference-based pricing

in British Columbia. Dr. Blough has

contributed to medical risk adjustment

methodology and to the development of

risk adjustment technology. His areas of

emphasis are generalized linear models,

the analysis of longitudinal data, and

mixed models.

Emily Beth Devine, PharmD, MBAResearch Assistant ProfessorAssociate Director, PORPPDr. Devine earned her doctorate in

Pharmacy from the University of the

Pacific and her MBA from the University

of San Francisco. She completed her

residency in clinical pharmacy practice

at the Veterans Affairs Medical Center

in Palo Alto, CA, and a postdoctoral

fellowship in pharmacoeconomics and

outcomes research with the UW. Her

research interests include patient safety,

pharmacoeconomic analyses of

hepatitis, and patients’ quality of life.

She serves on the executive committee

of the Section of Clinical Specialists of

the American Society of Health-System

Pharmacists, where she strives to

strengthen the role of the pharmacist in

research. She is also a member of the

International Society for Pharmaco-

economics and Outcomes Research.

Jacqueline S. Gardner, PhDAssociate ProfessorDr. Gardner earned a PhD in Epidemiology

from the UW School of Public Health and

Community Medicine in 1980. From 1980

to 1992, she worked for The Upjohn

Company, ultimately becoming Director of

Drug Epidemiology. Dr. Gardner’s research

focuses on the use and effects of drugs in

women and children, and on innovative

pharmacy practice. Her projects have

included examination of the use ofhormone replacement therapy by meno-

pausal women and the association of

maternal drug use during pregnancy with

craniosynostosis. She is responsible for

evaluating demonstration projects

designed to explore the outcomes of

extending prescriptive authority to

pharmacists to provide emergency contra-

ception. Dr. Gardner is a member of the

Washington State Pharmacy Association,

the Drug Information Association, the

International Society of Pharmaco-

epidemiology, the American Pharmaceu-

tical Association, and the Association of

Reproductive Health Professionals.

Milo Gibaldi, PhDDean Emeritus, School of PharmacyProfessor, Pharmaceutics and PharmacyFrom 1978 to 1995, Dr. Gibaldi was Dean of

the UW School of Pharmacy, where he also

was Associate Vice President for Health

Sciences and Chair of the Board of Deans.

He is a fellow of the Academy of Pharma-

ceutical Sciences and the American

Association for the Advancement of

9

includes an evaluation of reference pricing

in British Columbia’s Pharmacare pharma-

ceutical benefit and 3-tier co-payment

programs with Washington health insurers.

He is also interested in systems analysis of

medication errors in community pharmacy

practice and automation opportunities for

their amelioration.

Eric S. Johnson, PhDAssistant ProfessorDr. Johnson specializes in the design of

epidemiologic studies that evaluate drug

safety and describe the outcome of illness.

Most of his research investigates patients

with diabetes using population-based

registries and insurance databases. He

collaborates with investigators at the Center

for Health Research at Kaiser Permanente

Northwest. Dr. Johnson teaches a graduate

course on pharmacoepidemiology and

another on the principles of publishing

clinical evidence. He began his career in

epidemiology in 1991 at the US Centers

for Disease Control and Prevention,

evaluating blood product safety. He

earned an MPH in Health Services Research

in 1994 with a concentration in outcomes

research, and his PhD in Epidemiology

in 1999, both at the UW. Prior to joining

the Department of Pharmacy, Dr. Johnson

worked as an epidemiologist for Epide-

miology Resources, Inc. in Massachusetts.

He is a member of the International Society

of Pharmacoepidemiology and the

American Diabetes Association.

Donald L. Patrick, PhD, MSPHProfessorDr. Patrick is Senior Investigator, Center for

Disability Policy and Research, and Chair,

Social and Behavioral Sciences Program

Committee in the Department of Health

Services of the UW School of Public Health

and Community Medicine. He also directs

the Biobehavioral Cancer Prevention and

Control Training Program. In addition to

his appointment in PORPP, he holds

appointments in the Departments of

Epidemiology, Sociology, and Rehabilita-

tion Medicine. He publishes widely in the

areas of health status and quality of life

outcomes assessment, end-of-life care,

disability policy and research, health

promotion for older adults and persons

with disabilities, community intervention

and research, community priorities for

health care, resource allocation, and cost-

utility analyses. Dr. Patrick is a member of

the Institute of Medicine, the National

Academy of Sciences, and a Fellow of the

Academy for Health Services Research and

Health Policy.

Scott D. Ramsey, MD, PhDAssociate Professor and Director,Cancer Outcomes Research Program,Fred Hutchinson Cancer Research CenterDr. Ramsey earned his MD from the

University of Iowa and a PhD in Economics

from the Wharton School at the University

of Pennsylvania. He completed his

residency in internal medicine at the UW,

and was Chief Medical Resident for the

University Hospital. He also completed a

General Internal Medicine fellowship at the

Seattle VA Medical Center. He is Director

of the Cancer Outcomes Research Program

at the Fred Hutchinson Cancer Research

Center. He has served as the Health Analyst

for the US Senate Budget Committee. His

areas of interest include methods for

economic analyses in conjunction with

clinical trials, cost-effectiveness of genetic

screening for hereditary colon cancer, and

quality of life for cancer survivors and

colon cancer survivors. His current projects

include cost-effectiveness and quality of life

analyses of colon cancer screening and lung

reduction surgery for severe emphysema, an

economic evaluation of genetic screening

for colorectal cancer susceptibility, and a

project to compare the cost of therapies for

advanced lung cancer. Dr. Ramsey serves on

the editorial advisory boards of Expert

Review of Pharmacoeconomics & Outcomes

Research and the American Journal of

Managed Care.

Sean D. Sullivan, PhDProfessor and Director, PORPPDr. Sullivan earned his PhD in Health

Economics and Policy from UC Berkeley, an

MS in Pharmacy Administration from the

University of Texas, and a BS in Pharmacy

from Oregon State University. He com-

pleted a fellowship in Health Policy at the

UCSF Institute for Health Policy Studies,

and an NIH-funded fellowship in the

Economics of Aging at UC Berkeley. He

serves as principal investigator or co-

investigator on numerous health services

research and pharmaceutical costs and

outcomes assessment grants and contracts

and has published more than 100 papers,

book chapters, and books. He serves on the

editorial boards of PharmacoEconomics,

Pharmacotherapy, and Value in Health. His

research interests include the evaluation of

economic and health outcomes of interven-

tions for respiratory disorders, end-stage

renal disease, diabetes, cardiovascular

disease, osteoporosis, and mental health

disorders.

David L. Veenstra, PharmD, PhDAssistant ProfessorDirector, Postdoctoral PharmD ProgramsDr. Veenstra graduated from UC San

Francisco, where he completed concurrent

doctoral programs in Clinical Pharmacy

and Medicinal Chemistry. In medicinal

chemistry, his research centered on the

effect of amino acid mutations on protein

stability using computer modeling

techniques. Dr. Veenstra then conducted his

postdoctoral training in pharmaco-

economics with the UW from 1997–1999,

and spent one year working with Roche

Global Pharmacoeconomics in Palo Alto,

Scott Ramsey at spring picnic 2002

10

California. His methodologic expertise is in

cost-effectiveness modeling, including

decision analysis, Markov modeling, and

Monte Carlo simulation. His primary

research interests are the clinical, economic,

and policy implications of pharmaco-

genomic-based drug therapies. His projects

include studying the association between

drug metabolizing enzymes and adverse

drug reactions, estimating the cost-

effectiveness of pharmacogenomic

interventions, and evaluating the impact

of pharmacogenomics on the health care

system and pharmaceutical industry. He

holds a faculty appointment with the UW

Institute for Public Health Genetics. He has

experience in modeling chronic diseases

such as diabetes, hyperlipidemia, hyperten-

sion, and hepatitis B and C. As part of an

Academy of Managed Care Pharmacy

educational program, Dr. Veenstra has been

working with Pharmacy and Therapeutics

committees to assist them in evaluating

cost-effectiveness models submitted to

health care plans by manufacturers.

Dr. Veenstra is a member of the Society for

Medical Decision Making, the International

Society for Pharmacoeconomics and

Outcomes Research, and the American

Association for the Advancement of

Science. Dr. Veenstra is a recent recipient

of the Pharmaceutical Research and

Manufacturers Association Foundation

Career Development Award in Pharmaco-

economics.

Auxiliary FacultyD. S. (Pete) Fullerton, PhDAffiliate ProfessorDr. Fullerton is Vice-President of Pharmacy,

Regence Blue Shield. His expertise is in

achieving best practices in the managed

care environment. Specifically, he had led

the initiative entitled the Regence Format

for Formulary Submissions, a standardized

format for the submission of clinical and

economic information in support of

formulary consideration to Regence. This

effort has now evolved into the AMCP

(Academy of Managed Care Pharmacy)

Format for Formulary Submissions.

David Smith, RPh, MHA, PhDAffiliate Assistant ProfessorDr. Smith earned his pharmacy degree from

the University of Washington in 1990,

completed a residency in clinical pharmacy

and worked as a clinical pharmacist in

home care for several years. He received a

Master’s in Health Services Administration

in 1995, and was awarded a PhD in

Pharmaceutical Outcomes Research from

UW in 1998. He was the first doctoral

student to graduate from the PORPP

program. He then completed postdoctoral

work in economics at the University of

York, before returning to the Pacific

Northwest to conduct research with the

Kaiser Permanente Center for Health

Research in Portland, Oregon. His research

interests are in the economic evaluation of

health care technologies and pharmaco-

epidemiology.

Andy Stergachis, PhDAffiliate ProfessorDr. Stergachis is Senior Pharmacy Advisor

for drugstore.com and Principal and

Co-Founder of Formulary Resources, LLC.

He is an Affiliate Professor of Pharmacy

and Epidemiology at UW, and is affiliated

with The Hope Heart Institute in the area

of pharmaceutical research. Dr. Stergachis

served as Vice President and Chief

Pharmacist for drugstore.com, guiding

the organization from its prelaunch stage

through its present-day status as the

leading online drugstore. Formerly, he was

Chair of the UW Department of Pharmacy

and Founding Director of PORPP.

Previously, he worked for Group Health

Cooperative of Puget Sound in pharmacy

administration, and conducted health

research at the Center for Health Studies.

He earned his pharmacy degree from

Washington State University and his MS

and PhD in Pharmacy Administration from

the University of Minnesota. Dr. Stergachis

completed a postdoctoral fellowship in

health services research at the St. Louis Park

Medical Center, Minneapolis, Minnesota.

He was the 1990 Burroughs Wellcome

Scholar in Pharmacoepidemiology. The

American Association of Pharmaceutical

Research Scientists awarded him the 1994

Research Achievement Award in Economic,

Marketing, and Management Sciences. In

1999, American Druggist selected him as

one of the most influential pharmacists in

the United States. He has served as an

advisor to the National Institutes of Health,

the Agency for Healthcare Research and

Quality, and the Institute of Medicine.

He has published over 100 articles, book

chapters, and monographs, including work

in pharmacoepidemiology, managed care

pharmacy, internet pharmacy, and

pharmaceutical outcomes research. He

serves on the advisory boards of publica-

tions including the Hope Health Newsletter

of the Hope Heart Institute, P & T–

Pharmacy and Therapeutics, Pharmaco-

epidemiology and Drug Safety, Oncology

Economics, and the Journal of Managed

Care Pharmacy.

StaffCindy BushProgram Operations CoordinatorMs. Bush coordinates the Graduate and

Fellowship Programs. She also creates and

develops promotional materials, including

the PORPP web pages, and serves as the

contact person for current and prospective

faculty, fellows, students, and staff.

Penny EvansProgram CoordinatorMs. Evans coordinates the PORPP

programs including continuing education

conferences, seminars, and special events.

She also assists in the editing, preparation,

and dissemination of the quarterly

newsletter, The PORPP Report.

11

facult y focus

and the

UW extension certificate

program in biomedical

regulatory affairs

D r. (Tom) Hazlet’s background is notable for his work in the

regulatory affairs arena. He has used his experience as a Food

and Drug Scientist with the California Department of Health

Services, a member of the FDA’s Pacific Region Biotechnol-

ogy Team, and as an industrial manager in the pharma-

ceutical industry, to springboard to his current endeavor—

the UW Extension’s Certificate Program in Biomedical

Regulatory Affairs. Tom’s leadership, along with that of

colleagues in local industry, FDA, and the UW School of Law

and College of Engineering, has led to the creation of the

Certificate Program.

The eight-month evening certificate program’s course-

work provides a comprehensive overview of the knowledge

and skills necessary to be an effective regulatory affairs and

compliance specialist. Classes meet one evening per week in

Bellevue, Washington. In the first quarter, the course surveys

government oversight of drug, medical device and biotech-

nology-derived products; the laws and regulations that apply

to their development, testing and production; and the

responsibilities of a regulatory affairs specialist in the

regulatory setting. The second quarter emphasizes product

development and manufacturing concerns (such as quality

control, scale-up, good manufacturing practices and quality

systems), the FDA inspection process and FDA regulatory

actions. The third quarter focuses on post-marketing

requirements, reporting, and enforcement actions; emphasis

is on inspection—preparation, conduct of, and follow-up

actions. Post-marketing surveillance and studies, reimburse-

ment, and pharmacoeconomics issues are discussed.

Upon completion of the certification program, students

are eligible for employment opportunities where responsi-

bilities include overseeing the design, development, testing

and production of biologics, drugs and devices in the

industry setting.

Part of the certificate program’s richness derives from the

students, most of whom are employed by local manufactur-

ers. School of Pharmacy professional and graduate students

with an interest in manufacturing are encouraged to attend.

Significant interest in the certificate program has spurred

development of others. A certificate program in clinical trials

is nearing completion through UW Educational Outreach.

Future plans include the development of a graduate-level

certificate that includes courses from law, biomedical

engineering and business.

11

t h o m a s k . h a z l e t

12

Returning StudentsStudents in their second through fourth years ofthe PhD program:

Deborah Atherly, MPH

Debbie received a BS in Pharmacy and an MPH

from the UW. She joined the PhD program from

Parke-Davis Pharmaceuticals. Prior to that, she

worked at Regence Blue Shield, where she was

Director of Pharmacy and Formulary Manager.

She participated in the development of the

Regence (now AMCP) Format for Formulary

Submission Guidelines. In addition to a keen

interest in promoting the necessity of including

pharmacoeconomic data in the formulary

process, she is also interested in resource alloca-

tion in developing countries, HIV/AIDS, and

vaccines.

Denise Boudreau, MS, PhD Candidate

Denise earned both her BS in Pharmacy and her

MS in Pharmacy Administration at the University

of Rhode Island. A fourth-year PhD student,

Denise’s dissertation work brings together the

area of pharmacoepidemiology with issues in

breast cancer and women’s health.

Brian Custer, MPH, PhD Candidate

Brian received his BS in Biology from the Univer-

sity of Oregon and his MPH in Epidemiology at

the UW. His areas of interest include infectious

disease health outcomes, epidemiology, and

resource allocation. His PhD dissertation project

is focused on blood donation and blood product

safety. Other research interests include vaccine

development and the use of biotechnology in

health and medicine.

Thy Do, MS, MPH

Thy, a second-year PhD student, received his MS

from the State University of New York Stonybrook,

and his MPH from Yale University. Thy’s primary

interest is in the area of pharmacoepidemiology.

Our Students & Fellows new & returning

New StudentsIn the fall of 2001, PORPP welcomed threestudents to the graduate program inpharmaceutical outcomes:

Dana L. Hurley, PharmD

Dr. Hurley received both her BS in Pharmacy

and her PharmD from UW. She is employed as a

Clinical Outcomes Pharmacist at Premera Blue

Cross. Dana is pursuing the MS degree. Her areas

of research are cardiovascular and respiratory

diseases health outcomes.

Matthew Kerrigan, MSc

Matthew earned his BSc in Economics from the

University of Bradford in the United Kingdom

(UK), and his MS in Health Economics from the

University of York, UK. He joins us from Roche

Pharmaceuticals in Basel, Switzerland, where he

managed projects in pharmacoeconomics and

health technology assessment. Matthew is

enrolled in the PhD program.

Sarika S. Ogale, MS

Sarika received her BS in Pharmacy from Poona

College of Pharmacy in Pune, India, and her MS

in Pharmacy Administration from the University

of Louisiana at Monroe. She is enrolled in the

PhD program.

Our three new

students in the

graduate program in

pharmaceutical

outcomes (l to r):

Matthew Kerrigan,

Sarika Ogale,

Dana Hurley

13

Christopher Flowers, MS, MD

Dr. Flowers holds a BS degree in Human Biology,

a Master’s in Medical Information Sciences, and

an MD degree, all from Stanford University. He

is completing a second Master’s with PORPP.

He is enrolled in the UW/Robert Wood Johnson

Foundation Clinical Scholar’s program. His areas

of interest are the use of computer-based utility

assessment methods to examine drugs’ quality-of-

life benefits, and toxicity in phase I/II and phase

III oncology clinical trials.

Kristin Marciante, MPH, PhD Candidate

Kristin, a fourth-year PhD candidate, received

her BS in Biology and her MPH in Epidemiology

from Emory University. Her areas of interest

are clinical epidemiology and health program

evaluation. She has focused on contraception and

diabetes. Her dissertation project, “Modeling the

long-term, population-based outcomes of diabetic

retinopathy,” includes three studies: a validation

study of diagnosis and procedure codes used

to identify Kaiser Permanente type 2 diabetes

patients with retinopathy; an evaluation of Kaiser

Permanente type 2 diabetes patients’ adherence to

retinopathy screening and treatment guidelines;

and construction of a simulation model used to

estimate the incremental effectiveness of different

retinal screening strategies for preventing vision

loss in type 2 diabetics.

Nina Oestreicher, MS

Nina obtained her BS in Finance and Economics

from The Wharton School, University of Pennsyl-

vania. She received her MS in Epidemiology from

the UW. She is in her second year of the PhD

program. Her interest areas include analyses of

economic and health outcomes in cancer screening

and treatment, cardiovascular disease treatment,

genetic testing, and pharmacogenomics.

Karen Smith, BS

Karen received her BA in Biology from Sweet

Briar College in Virginia, and her BS in Pharmacy

from the University of Montana. In her second

year of the PhD program, Karen is interested in

costing and economic evaluations.

Scott Strassels, PharmD

Dr. Strassels received his PharmD

from the University of Arizona. After

completing a postdoctoral fellowship

in pharmacoeconomics with the UW

and GlaxoSmithKline, and practicing

pharmacy at the New England Medical

Center, Dr. Strassels returned to study in

the PhD program. His research interests

include epidemiology, economics, analgesia,

and chronic respiratory disease.

FellowsPORPP sponsors a postdoctoral fellowship inPharmacoeconomic and Outcomes Researchwith Roche Global Pharmacoeconomic Groupin Basel, Switzerland. This fellowship is designedfor Doctor of Pharmacy graduates who wish toenhance their skills in pharmacoeconomics andoutcomes research, and to prepare for employ-ment in the pharmaceutical or managed careindustries, or with policy-makers. Dr. DavidVeenstra is the Director of the FellowshipProgram.

Joanna C. Huang, PharmD

UW/Roche Pharmacoeconomic Fellow, 2000–2002

Dr. Huang received a BS degree in Chemistry and

Biology from Boston University in 1994, and her

PharmD degree from the UCSF in 2000. While

in school, she received Howard Hughes Medical

Institute funding for research in molecular

biology and genetics, and was an active member

of the California Pharmacists Association and the

California Society of Health-System Pharmacists.

Kavita K. Patel, PharmD, MBA

UW/Roche Pharmacoeconomic Fellow, 2001–2003

Dr. Patel received both her PharmD and MBA

from Drake University in 2001. While there, she

worked as a research assistant and conducted

drug utilization evaluations for the Pharmacy and

Therapeutics Committee. She is a member of the

International Society for Pharmacoeconomics

and Outcomes Research, the American Society of

Health-System Pharmacists, and the Illinois and

Iowa Pharmaceutical Associations.

he benefits of

PORPP are easy

to state:

the program

provides a

strong

grounding in

health

outcomes

research

coupled with

unlimited

opportunities

for student

collaboration

with the faculty.

—Brian Custer

t

13

14

Honors & Awards

FacultyDr. Jacqueline Gardner received the

Washington State Pharmacy Association

Special Achievement Award in 2001.

During 2001, Dr. Donald Patrick was

recognized with both the Robert Wood

Johnson Senior Health Policy Investigator

Award and the President’s Award, Interna-

tional Society for Quality of Life Research.

After completing a postdoctoral fellowship

at the University of York Centre for Health

Economics in 2000, Dr. David Smith was

appointed as an Honorary Visiting Research

Fellow at the University of York. This

appointment reflects ongoing collaboration

with researchers at York.

Dr. Andy Stergachis presented two guest

lectures: as the Melendy Lecturer at the

College of Pharmacy, University of Minne-

sota, and the Katterman Lecturer at the

School of Pharmacy, University of Washing-

ton, in 2000. In 2002, he also received the

APhA Foundation’s Pinnacle Award, which

recognizes individual career achievement

and contributions to health care quality

through improving the medication-use

process.

Dr. Sean Sullivan chaired the 6th Annual

(2001) International Meeting of the

International Society for Pharmaco-

economics and Outcomes Research.

Dr. David Veenstra received a Faculty

Development Award in Pharmaco-

economics, sponsored by the PhRMA

Foundation, and presented at the

6th Annual (2001) International

Meeting of the International Society for

Pharmacoeconomics and Outcomes

Research.

StudentsReceiving recognition at the 6th Annual

(2001) International Meeting of the

International Society for Pharmaco-

economics and Outcomes Research, were

students Debbie Atherly and Nathorn

Chaiyakunapruk, and faculty advisor

Sean Sullivan. Their poster was entitled

“Cost Impact of COX-2 Inhibitors in a

Managed Care Plan: Implications for

Formulary Decision-making.” Debbie was

interviewed for this research in the May

28, 2001 issue of the “Pink Sheet.”

Denise Boudreau received predoctoral

fellowship support from both the

American Council on Pharmaceutical

Education (2001 and 2002) and the

Pharmaceutical Research and Manufac-

turers of America Foundation Program

in Health Outcomes Research (2002).

Dr. Nathorn Chaiyakunapruk was the

recipient of the William A. Rutala Award

at the Association for Professionals in

Infection Control and Epidemiology, Inc.

(APIC) 2001 Annual Educational

Conference and International Meeting,

held in Seattle, on June 11, 2001. He

received this award for the abstract of his

dissertation research, “Which Antiseptic

Should We Use for Vascular Catheter Site

Care?” The APIC Abstract Selection

Committee nominates the top abstracts

in the category of disinfection, steriliza-

tion, and antisepsis. Selection of the

winning abstract is made by Dr. Rutala, a

world-renowned expert in the fields of

infection control, disinfection, steriliza-

tion, and medical waste.

Brian Custer received the Achievement

Reward for College Scientists (ARCS) for

1999–2002. The ARCS fellowship program

faculty & students

above:

Mitch Higashi in front of

his award-winning

poster at the 6th Annual

(2001) International

Meeting of the

International Society

for Pharmacoeconomics

and Outcomes Research.

opposite page:

Nina Oestreicher and

Kristin Marciante at

spring picnic 2002

15

Program is part of the Warren G.

Magnuson Institute for Biomedical

Research and Health Professional

Training, established in 1991 in honor of

the late Washington senator. The year

2001 marks the third year in a row that

Kristin has received the honor of this

scholarship. In 2000, she also received her

third and final year of the Achievement

Reward for College Scientists (ARCS).

Nina Oestreicher is the recipient of the

American Foundation for Pharmaceutical

Education predoctoral fellowship for

2002-2003. The primary goal of the AFPE

Fellowship program is to identify and

support those students who have the

potential to become leaders in the

pharmaceutical profession.

Holly Trautman is the recipient of the

2000 Facts and Comparison Award for

Excellence in Clinical Communication.

She completed her Master’s Degree with

support from the AstraZeneca Fellowship

in Managed Care Pharmacy (2001).

was begun following the launch of

Sputnik to provide three-year scholarships

to deserving students in the fields of

natural science, medicine, and engineer-

ing. To support his dissertation work,

Brian Custer has also received a Fellow-

ship in Blood Donor Epidemiology (2002)

from the Blood Systems Foundation.

Thy Do was awarded the Achievement

Reward for College Scientists (ARCS) in

2000, which is renewable for three years.

Mitch Higashi received the Best Poster

Presentation award at the 6th Annual

(2001) International Meeting of the

International Society for Pharmaco-

economics and Outcomes Research. His

work was entitled, “The Cost-Effectiveness

of Genetic Testing for Periodontal Disease:

A Payer’s Perspective.” In support of his

dissertation research, he received a grant

from the National Institute of Environ-

mental Health Sciences to study the effect

of CYP2C9 genotype on anticoagulation-

related outcomes during warfarin therapy;

and a grant from the UW Institute for

Public Health Genetics to study the cost-

effectiveness of implementing genetic

screening at anticoagulation clinics prior

to initiation of warfarin therapy.

In support of her master’s program,

Dr. Dana Hurley received support from

the AstraZeneca Fellowship in Managed

Care Pharmacy (2001–2002).

During the time he was a PhD candidate,

Dr. Todd Lee received a predoctoral

fellowship from the American Council on

Pharmaceutical Education to support his

dissertation work.

Kristin Marciante is the recipient of the

Magnuson Scholar Award. The Scholars

reat scientists and great

surfers share a common

trait. They don’t posi-

tion themselves where

the big wave is now,

they position themselves

where the next big wave

is going to be. PORPP

teaches students to read

the patterns in scientific

methods, to understand

the history that built up

behind the last big

waves, and to prepare

for the ride of your life

when you finally catch

the big one.

—Mitch Higashi

g

15

16

During

2000–2002,

PORPP

faculty

received over

$1.9 million

in funding—

$268,000 in

federal funds,

$1.5 million

in private

funds, and

$180,000 in

graduate

student

grants.

Research Programs & Grants

Program faculty have received funding from private and government entities to conduct research projects related to

pharmaceutical outcomes and policy. Major studies are underway on the health and cost outcomes of infectious

diseases; of chronic diseases such as asthma, hypertension, depression, schizophrenia, and end-stage renal disease; on

the safety of selected pharmaceutical and biotechnology products; and on pharmaceutical care practice issues.

for Child Health and Human

Development of National

Institutes of Health

Principal Investigator: GardnerCo-investigator: Marciante

Increasing Access to Emergency

Contraception in Rural Areas of

Washington State

Funding Source: Washington State

Dept. of Social and Health Services

Principal Investigator: Gardner

Outreach Services Center

(Provides consultative and profes-

sional services to the community)

Funding Source: Self-sustaining

Principal Investigator: Gardner

Health Costs and Outcomes with

Three-Tier Pharmacy Insurance

Benefit Plans

Funding Source: Aetna Quality

Care Research Fund

Principal Investigators: Hazlet and

BloughCo-investigators: Atherly, Fullerton,

Hurley, Sullivan, and Veenstra

Evaluation of an Intervention to

Improve Control of Type 2

Diabetes Mellitus, Medication

Adherence, and Medication Safety

in Adults

Funding Source: Aetna Quality

Care Research Fund

Principal Investigator: Odegard

Co-Investigators: Blough and

Johnson

Pre-Doctoral Fellowship in Blood

Donor Epidemiology

Funding Source: Blood Systems

Foundation

An investigation of the cost

effectiveness of nationally promoted

pediatric asthma guideline in three

managed care populations.

Funding Source: Agency for

Healthcare Research & Quality

Principal Investigator: SullivanCo-investigator: Blough

Benzodiazepine Use and Risk

of Disability in the Elderly

Funding Source: National

Institutes of Health

Principal Investigator: GrayCo-investigator: Blough

Cost and Outcome Evaluation

of Guideline Implementation for

the Treatment of Depression in

an Academic Medical Center

Managed Care Setting

Funding Source: Aetna Foundation

Principal Investigator: SullivanCo-investigator: Blough

Development and Validation of a

COPD Symptom-based Outcome

Measure

Funding Source: Genentech, Inc.

and Inspire Pharmaceuticals

Principal Investigator: SullivanCo-investigator: Blough

The Efficacy of Parental

Educational Materials in Reducing

Antibiotic Use

Funding Source: Aetna Foundation

Principal Investigator: Taylor

Co-investigator: Blough

Improving Contraceptive Practice

and Delivery through Community

Pharmacies

Funding Source: National Institute

Principal Investigator: JohnsonCo-investigator: Custer

Review of methods for measuring

drug therapy discontinuation

Funding Source: Pharmacia Corp.

Principal Investigator: Johnson

The Epidemiology and Cost of Drug

Therapy for Diabetes: A Population-

Based Cohort Study

Funding Source: GlaxoSmithKline

Principal Investigator: Johnson

Biobehavioral Cancer Prevention

and Control Training Program

Funding Source: National Cancer

Institute

Principal Investigator: Patrick

Development of a Clinical Tool for

Assessing Physical Activity Among

Older Adults

Funding Source: Centers for Disease

Control

Principal Investigator: Patrick

Managed Care and Physician

Satisfaction

Funding Source: Agency for

Healthcare Research and Quality

Co-investigator: Patrick

Quality of Life Among Youth with

Craniofacial Conditions: Phase II

Study

Funding Source: National Institute

for Dental and Craniofacial Research

Principal Investigator: Patrick

The Family Experience Pilot Study

Funding Source: Eli Lilly & Company

Principal Investigator: Patrick

Biobehavioral Cancer Prevention &

Control Training Program

‒

17

t

17

he PORPP

program has

enabled me to

not only have

an enriching

academic

experience,

but also has

given me the

opportunity

to collaborate

with a strong,

diverse group

of highly

talented and

experienced

individuals.

—Kavita Patel

The Cost effectiveness of Phot-

dynamic Therapy with

verteporftin

Funding Source: Novartis

Co-Investigator: Smith

Drug Safety Surveillance

Using United Health Group’s

Linked Databases, 2002-2004

Funding Source: Food and

Drug Administration

Principal Investigator: Shatin

Co-investigator: Stergachis

Costs, Outcomes and Cost-

Effectiveness of Dental

Services

Funding Source: Washington

Dental Services

Principal Investigator: Sullivan

Early Intervention with

Steroids in Asthma

Funding Source: AstraZeneca

Principal Investigator: Sullivan

Economic Model of Bipolar I

Disorder

Funding Source: GlaxoSmithKline

Principal Investigator: Sullivan

Graduate Research Fellowship

Funding Source: AstraZeneca LP

Principal Investigator: Sullivan

The Clinical and Economic

Implications of Genetic

Testing for Individualized

Drug Therapy: Warfarin and

the CYP2C9 Gene

Funding Source: UW Institute

for Public Health Genetics

Principal Investigator: Veenstra

The Role of Pharmaco-

genomics in the Genomics

Revolution

Funding Source: PhRMA

Foundation

Principal Investigator: Veenstra

UW/Roche Postdoctoral

Fellowship in Pharmaco-

economics Research

Funding Source: Roche Global

Pharmacoeconomic Research

Principal Investigator: Veenstra

development award)

Funding Source: National Cancer

Institute

Principal Investigator: Ramsey

The cost-effectiveness of lung

volume reduction surgery

Funding Source: National Heart,

Lung, and Blood Institute

Principal Investigator: Ramsey

Modelling the Long-Term, Popula-

tion-Based Outcomes of Diabetic

Retinopathy

Funding Source: Self-funded

Principal Investigators: Johnsonand Smith (with Marciante)

Analysis of 5-year secular trends in

antibiotic prescribing (1995–1999);

Examination of medication pre-

scribing patterns and impact on out-

comes for hospitalized heart failure

patient; Changes in the use of oral

antidiabetic agents associated with

medication co-payments.

Funding Source: Agency for Health-

care Research and Quality, HMO

Centers for Education and Research

in Therapeutics, (HMO CERTs).

Co-Principal Investigator: Smith

Describing the frequency of potential

errors of medication prescribing

black box warnings, drug lab moni-

toring, dosing in renal insufficiency,

drug use in the elderly, and drug

interactions; The use of alerts in the

electronic medical record (at Kaiser

Permanente Northwest) at time of

clinician medication order entry.

Co-Principal Investigator: SmithFunding Source: Agency for Health-

care Research and Quality, HMO

CERTs

Outcomes and Resource Use for

those with Kidney Dysfunction

Funding Source: Amgen

Principal Investigator: Smith

Modelling the Cost-effectiveness

of Oral Cancer Screening

Funding Source: The Health Tech-

nology Assessment Programme, UK

Co-Investigator: Smith

Funding Source: National Cancer

Institute R25 Training Grant

Principal Investigator: PatrickCo-Principal Investigator: Ramsey

Burden of illness and direct costs of

medical care of colon cancer

Funding Source: Aetna Foundation

Principal Investigator: Ramsey

CanCORS: Lung/Colon Cancer

Outcomes: Cancer Research Network

Funding Source: National Cancer Inst.

Principal Investigator: Weeks

Co-Investigator and Principal

Investigator for Special Project:

Ramsey

Correlation of Endoscopy Frequency

with Survival for Individuals

Diagnosed with Local and Regional

Colorectal Cancer

Funding Source: National Cancer

Institute

Principal Investigator: Ramsey

Evaluating the use of genetic

information. A model process

Funding Source: National Institute for

Human Genome Research

Principal investigator: BurkeCo-Investigator: Ramsey

Health Care Utilization and Direct

Medical Costs for Persons with Non-

Small Cell Lung Cancer

Funding Source: Bristol Myers Squibb

Principal Investigator: Ramsey

Interdisciplinary Model for Studying

Lung Cancer

Funding Source: FHCRC Institu-

tional Funds (Public Health Sciences

Division, Bid and Proposal Funding).

Principal Investigator: Ramsey

SEER Special Study #19: Feasibility

of Linking Health Systems Data to

Cancer Registry Data

Funding Source: National Cancer

Institute

Principal Investigator: Ramsey

The cost-effectiveness of genetic

screening for hereditary nonpoly-

posis colorectal cancer (Howard

Temin Award: 5-year career

18

PORPP

18

FA C U LT Y ACT I V I T I E S & SE RV I C E

CO R P O R AT E ADV I S O RY BOA R D

CO N F E R E N C E S & SY M P O S I A

FA C U LT Y FO C U S: SE A N SU L L I VA N

G R A N D R O U N D S S E M I N A R S E R I E SPha

rmac

euti

cal O

utc

omes

Res

earc

h a

nd

Polic

y P

rogr

am A C A D E M I C & C O M M U N I T Y I N T E R F A C E

19

Faculty Activities & Service

Dr. Jackie Gardner’s influence in the

arena of provision of emergency contra-

ception interventions by pharmacists has

led to a grant from the National Institute

for Child Health and Human Develop-

ment to study improved contraceptive

practice and delivery through community

pharmacies. It is a community-based

intervention study of the implementation

of a protocol to screen and supply

hormonal contraceptives through

community pharmacists. The study is

scheduled to be ongoing for four years.

Collaborators include Dr. Leslie Miller,

Director of Public Health Seattle-King

County Family Planning Clinics;

Stephanie Le, Fred Meyer Pharmacies;

and Don Downing, UW Department of

Pharmacy. PORPP faculty Dave Blough

and graduate student Kristin Marciante

will also participate.

Dr. Tom Hazlet’s success in studying

reference drug pricing in British Colum-

bia has led to receipt of a grant from the

Aetna Quality Care Research Fund to

study the health costs and outcomes with

three-tier pharmacy insurance benefit

plans in the Pacific Northwest of the US.

Drs. Scott Ramsey and Sean Sullivan

served on the national panel that

developed the “Guidelines for Prevention,

Screening and Treatment of Obstructive

Lung Disease.” The Guidelines are an

effort of the Global Obstructive Lung

Disease Initiative of the National Heart,

Lung, and Blood Institute, National

Institutes of Health, and the World

Health Organization.

Dr. David Smith was co-author on a

report that estimates the potential cost

and resource use implications of imple-

menting the mandate on reorganizing

cancer services from the influential

‘Calman-Hine’ report in the United

Kingdom. His report showed that a

critical factor in the cost of the reorgani-

zation would be the release of resources

from centers where care is currently

being provided. It was funded by the

Northern and Yorkshire Health Author-

ity, the largest Health Authority in the

UK, and provided a starting point for

policy negotiations on reorganization.

(Baughan S, Ferguson B, Hatfield A,

Smith DH, Wilkinson J. Implementing

Guidance Across Health Authorities: The

Case of Gynaecological Cancer. Nuffield

Portfolio Programme Report No. 11.

2000, University of Leeds)

Dr. Smith was also a co-investigator

on a report that is a part of the National

Beds Inquiry, a broad-based examination

of the need for additional inpatient ser-

vices in the UK National Health Service

and was commissioned by the Depart-

ment of Health. The report reviewed the

literature on avoidable use of inpatient

services and the cost-effectiveness of

alternatives to inpatient care. Ultimately,

recommendations from this report were

fed into the policy decision-making

process in the Department of Health.

(Goddard M, McDonagh M, Smith DH.

Avoidable use of Beds and Cost Effective-

ness of Care in Alternative Locations in

Shaping the Future NHS: Long Term

Planning for Hospitals and Related

Services. Consultation Document on the

Findings of the National Beds Inquiry—

Supporting Analysis. Published by the

NHS Executive. Crown Copyright 2000.)

Dr. Sean Sullivan evaluated the costs and

benefits of prescription drug discount

cards for the state of Washington. The

report was published pursuant to the

introduction of Washington State

Executive Order No. 00-04 to establish a

mechanism by which individuals age 55

and older, without current prescription

drug coverage, could obtain prescription

drugs from retail and mail order channels

of distribution at prices comparable to

those paid by the Washington State

Uniform Medical Plan (2001).

Along with experts from the Academy

of Managed Care Pharmacy, Sean Sullivan

led a national effort to standardize the

format of clinical and economic informa-

tion to support drug formulary decision-

making. The “AMCP Format for Formu-

lary Submissions” is being embraced by

managed care decision-makers and phar-

maceutical manufacturers nationwide.

Dr. David Veenstra’s work in the area of

pharmacogenomics is being well-received

in an environment where investigators,

clinicians and policy-makers are all

seeking information about how to apply

the theory of the human genome project

to clinical decision-making.

Policy Research ReportsThrough the years, PORPP faculty have been involved in the development of many

policy decisions, on both the state and national levels, where the work of PORPP

investigators informs decision-makers in a variety of areas. Below are highlighted

some of the recent contributions made by PORPP faculty. PORPP faculty are also

active on many advisory panels in their areas of specialty; and serve in leadership

positions with professional societies.

policy, panels, boards, societies

20

Jacqueline S. Gardner, PhD

Member, FDA Advisory Panel: Drug Safety and Risk Manage-

ment Subcommittee of the Pharmaceutical

Sciences Advisory Committee

Donald L. Patrick, PhD, MSPH

Consultant, Social Security Administration on Ticket to Work and

Work Incentives Improvement Act of 1999—Evaluation Advisor

(5 years)

Chair, NIH State-of-the-Art Conference on Treatment of Pain,

Depression and Fatigue

Consultant, European Union Development of Child Health Status

Measures

Scientific Advisor, Consumer Advisory Group, Model Spinal Cord

Injury System Grant, Northwest Regional SCI System

Scott D. Ramsey, MD, PhD

Advisory Board, Genentech, Inc.

Chair, FDA Medical Devices Dispute Resolution Panel

FDA Center for Devices and Radiologic Health

Andy Stergachis, PhD

Advisor, Verified Internet Pharmacy Practice Sites (VIPPS)

Program, National Association of Boards of Pharmacy

Board of Directors, Group Health Community Foundation

Health Systems Research Study Section of the Agency for

Healthcare Research and Quality

HEDIS Expert Pharmacy Panel, National Committee on Quality

Assurance

President-Elect and Board of Directors, Washington Poison Center

US-Swiss Joint Economic Commission. Planning Group for Panel

Discussion on “Bioterrorism: the Pharmaceutical Industry

Response” presented in conjunction with World Economic Forum,

New York, February, 2002

Sean D. Sullivan, PhD

Health Economics and Outcomes Research Advisory Board,

Aventis

Merck International Respiratory Advisory Board

Chair, Washington State Asthma Initiative, American Lung

Association of Washington

Advisory Panels & Corporate Boards

Professional SocietiesEmily Beth Devine, PharmD, MBA

Office of the Chair, Section of Clinical Specialists,

American Society of Health-System Pharmacists

(2000–2003)

D. S. Pete Fullerton, PhD

Incoming Member, Board of Directors, International

Society for Pharmacoeconomics and Outcomes

Research (2002–2004)

Sean Sullivan, PhD

Incoming Presidential Officer (2002–2004),

International Society for Pharmacoeconomics and

Outcomes Research

Dr. Jackie Gardner with

emergency contraception poster

at the 2002 Health Sciences

Open House

21

THE UW SCHOOL OF PHARMACY Corpo-

rate Advisory Board (CAB) first met in 1998 to

begin important discussions of areas of common

interest between faculty involved in pharmacy

education and corporate members of the

pharmaceutical industry. In late 2001, the CAB

reconvened to create a strategic partnership that

will propel PORPP into the future. On November

2, 2001, eleven colleagues from the pharmaceuti-

cal industry met with PORPP faculty for a day of

brainstorming ideas that will enhance our already

strong partnership, with the goal of strengthening

the PORPP program to meet the needs of

colleagues in the pharmaceutical industry. This

productive day concluded with a gathering atop

the Seattle World Trade Center, where Dean Sid

Nelson, Department Chair Dr. Danny Shen, and

the School of Pharmacy faculty welcomed CAB

members.

With the help of our CAB members, the

PORPP faculty were able to assess our current

levels of activity and plan our future goals in the

following areas:

■ Train researchers who understand the

perspective of, and are prepared to function at

a high level within the pharmaceutical

industry.■ Increase the number of PORPP graduates to

fill available positions in the pharmaceutical

industry.■ Develop the ability to respond to emerging

industry research needs, both in terms of

expertise of our graduates, and in terms of

faculty to conduct research (e.g., quality of life

and drug safety, respectively).■ Train those currently employed in the

industry setting, in the concepts of

pharmacoeconomics and outcomes research.

Corporate Advisory Board

y time as a

PORPP student has

been incredibly

fulfilling; I’ve made

lifelong friends and

received mentoring

from truly

outstanding faculty.

Thus, it is with a

mixture of sadness

and excitement that

I look forward to

graduating and

beginning a career

that will provide me

the opportunity to

apply the many

skills I’ve learned.

—Kristin Marciante

mCAB Members

Chair: Edward Bortnichak, MD, PhD

Sanofi-Synthelabo

Michael del Aguila, PhD

Washington Dental Services

D. S. (Pete) Fullerton, PhD, RPh

Regence Blue Shield

Louis Garrison Jr., PhD

Roche

Leonard Kirchdoerfer, PhD

Genentech

Grant Lawless, MD, RPh

Amgen

Sissi Pham, PharmD

GlaxoSmithKline

Phillip Sarocco, PhD

Aventis

Vipan Sood, RPh, MBA, MRPharmS

Pharmacia

Clifford Stocks, MBA

ICOS

Kent Summers, RPh, PhD

Lilly

21

strategic partnership

22

AMCP Format for Formulary SubmissionEducational SymposiaIn June 2001, in Vancouver, BC, PORPP faculty, along

with affiliated colleagues, conducted the first training

symposium for managed care practitioners on

implementing the AMCP Format for Formulary

Submission Guidelines. Presented in collaboration with

the Foundation for Managed Care Pharmacy, the

symposium was so well received that it became the

first of a repeated series in 2002. One and one-half

days in length, this symposium targets different

geographic areas of the United States to

train managed care decision-makers in the use of

the Format. Faculty included Drs. Pete Fullerton, Dell

Mather, Pete Penna, Scott Ramsey, Sean Sullivan,

David Veenstra, John Watkins, RPh, MPH, and from

AMCP—Steve Avey, RPh, and Richard Fry, RPh.

Spring ConferenceAn annual PORPP symposium, this year’s Spring

Conference featured an afternoon informing managed

care account executives and pharmaceutical industry

representatives about implementation of the AMCP

Format for Formulary Submission Guidelines by

managed care organizations. With over 100 attendees,

the symposium was held at the W Hotel in Seattle.

Faculty included Drs. Fullerton and Sullivan, Deborah

Atherly, RPh, MPH, and John Watkins, RPh, MPH.

Fall Clinical Conference

The annual PORPP Fall Clinical Conference was held

in October 2001, at the Elliott Grand Hyatt in Seattle.

Presented in partnership with the UW School of

Medicine, Division of Allergy and Infectious Diseases,

the UW School of Nursing, and the American Lung

Association, this conference reviewed “Therapeutic

Advances in Respiratory and Infectious Diseases.”

Attendees included practicing clinicians (medicine,

nursing, and pharmacy) in the Puget Sound area.

Presenting UW faculty included Drs. Henderson,

Redding, Shapiro, Hallstrand, Sullivan, Black and

Hansten.

Northwest Medical Director and Pharmacy BenefitManagers Quarterly Educational MeetingFall 2001 brought an opportunity for PORPP faculty

to share their expertise in a one-day program,

sponsored by the Northwest Medical Director and

Pharmacy Benefit Managers group, entitled “Critical

Evaluation of Clinical and Economic Data for

Formulary Decision-making.” Participating faculty

included Drs. Fullerton, Ramsey, Sullivan, Veenstra,

and John Watkins, RPh, MPH.

Managed Care Conference—Update on Treatmentand Management of Hepatitis CIn November 2001, PORPP sponsored a noontime

conference, presented by experts in the field of

hepatitis C. The “Update on Treatment & Management

of Hepatitis C” included speakers Willis Maddrey, MD,

University of Texas Southwestern Medical Center,

Dallas, and Robert Carithers, Jr., MD, University of

Washington. The audience included those in manage-

ment positions in regional health plans.

Attendees

at the

AMCP 2002

Formulary

Training

Symposium in

Orlando,

Florida

educational, clinicalConferences & Symposia

23

facult y focus

23

and the

AMCP Format for

Formulary Submission

Dr. Sean Sullivan, along with experts from the Academy of Managed Care Pharmacy

(AMCP), lead an effort to prepare a standardized format for the submission of

clinical and economic information to support drug formulary considerations

entitled, “The AMCP Format for Drug Formulary Submissions.” The document was

initially presented by Dr. Sullivan at the AMCP Educational Conference in San Diego

in October 2000. The Format is a tool intended for use by manufacturers when

submitting a dossier for drug formulary consideration by managed care organiza-

tions. Simultaneously, it is a tool for pharmacy directors to use in obtaining and

evaluating both clinical and pharmacoeonomic data provided by a pharmaceutical or

medical device company. The Format is a standardized template to draw evidence-

based conclusions about the clinical benefit and value of pharmaceuticals and

medical devices. The overarching purpose is to create more informed Pharmacy and

Therapeutics Committees nationwide—committees that are able to make increas-

ingly sound and rational formulary decisions.

Use of the Format has two goals. The first goal is to increase the timeliness,

comprehensiveness, and objectivity of information provided to the Pharmacy and

Therapeutics Committee. The second goal is to streamline the data acquisition and

review process for health plan pharmacists, as they undertake the evaluation process.

For example, with utilization of the Format, manufacturers are asked to provide

information about anticipated off-label uses of a product, thus enabling a more

informed decision for the health plan. Also unique to the Format is the request for an

economic model that demonstrates the anticipated populations in which the product

will provide the greatest value. Through collaboration between the pharmacists at

the health plans and benefit management organizations and the manufacturer, the

model can be tailored to the specific population under consideration, using data

from the health plan itself.

The precursor to the AMCP Format for Formulary Submissions was created by

pioneering work of Dr. Sullivan and three other PORPP members: Affiliate Professor

Dwight S. “Pete” Fullerton, PhD; former PORPP fellow Dell Mather, PharmD; and

PORPP graduate student, Deborah Atherly, RPh, MPH. Drs. Sullivan, Fullerton, and

Mather first created a set of formulary submission guidelines for use at Regence

BlueShield, a Seattle-based health plan covering 1.1 million lives. Ms. Atherly, as

Pharmacy Director and Formulary Manager, was an integral part of the development

process, providing important feedback that has led to their continual improvement

and eventual adoption by the prominent, national managed care organization for

pharmacists, AMCP.

The current focus of the developers is to increase awareness and utilization of

the Format nationwide. Since June of 2001, six educational symposia have been

conducted by the PORPP faculty, along with the AMCP Foundation. These symposia

have been provided in different locations throughout the United States. A separate

educational conference, targeted toward managed care industry liaisons, was recently

held in Seattle, and was well received.

From the global perspective, Australia, Canada, and other countries require

manufacturers to submit economic data and models when their products are

considered for inclusion in national formularies. The AMCP Format mirrors these

requirements, in a national environment wherein this information is not required,

but wherein interest in demonstrating value in the expensive marketplace of US

pharmaceuticals, is a welcome improvement.

The AMCP Format for Formulary Submissions can be viewed at:

http://www.amcp.org.

s e a n s u l l i v a n

24

Seminars 2000–2002Andrew Briggs, PhD

McMaster University, University of Oxford

Presenting Uncertainty in the Results of Cost-

Effectiveness Analysis to Aid Decision Making

for Disease Management, Specifically Diabetes

John Miall

Health Benefits Manager, City of Asheville

North Carolina

The Cost Benefit of Utilizing a Community

Pharmacist

Peter J. Neumann, DSc

Assistant Professor of Policy and Decisions

Sciences, Harvard School of Public Health

The FDA’s Regulation of Health Economic

Claims

Gerry Oster, PhD

Policy Analysis, Inc., Boston, Massachusetts

Designing and Analyzing Large, Simple Cost-

Effectiveness Trials

Grand Rounds Seminar Series

Cost and Outcomes SeriesThe Cost and Outcomes Grand Rounds

Seminar Series was established by PORPP in

1997 to provide a forum for leading experts

in cost and outcomes assessment to present

clinical and economic research concepts and

methods to UW researchers and trainees, as

well as members of the Seattle-area research,

health insurance, pharmaceutical,

biopharmaceutical, and medical device

industries. The Cost and Outcomes Grand

Rounds is jointly sponsored by PORPP, the

UW Center for Cost and Outcomes Research,

and the Outcomes Affinity Group at the Fred

Hutchinson Cancer Research Center.

Our most recent guest was Peter J.

Neumann, DSc, Assistant Professor of Policy

and Decision Sciences at the Harvard School

of Public Health. PORPP Director Sean

Sullivan welcomed Dr. Neumann on October

24, 2001. Dr. Neumann spoke to his audience

on “The FDA’s Regulation of Health Economic

Claims.” His talk stressed the importance and

evolutionary nature of this topic.

above: (l to r): Chris Flowers, Tom Hazlet, Sarika Ogale,

Karen Smith, and David Veenstra at Seminar

opposite page: Home of the UW School of Pharmacy

25

PORPP

25

NE W FA C U LT Y

FA C U LT Y FO C U S: DAV I D VE E N ST R A

NE W ALU M N I

VI S I T I N G SC H O LA R S

GR A D UAT E PRO G R A M RE V I E W

GR A D UAT E EM P L OY M E N T

SE L E CT E D PU B L I CAT I O N S

GR A N TS, GI F TS & AF F I L I AT I O N S

Pha

rmac

euti

cal O

utc

omes

Res

earc

h an

d Po

licy

Pro

gram O U R P R E S E N T ; O U R F U T U R E

26

New FacultyAssociate DirectorEmily Beth Devine, PharmD, MBA

In August 2001, PORPP welcomed Emily Beth

Devine as Associate Director and Research

Assistant Professor. Dr. Devine brings her

research, leadership, and clinical and business

skills to the PORPP program, and is looking

forward to advancing the program. She joined

PORPP upon completion of her UW/Roche

postdoctoral fellowship in pharmacoeconomics

and outcomes research. Dr. Devine earned her

doctorate in Pharmacy from the University of

the Pacific and her MBA from the University

of San Francisco. She completed her residency

in clinical pharmacy practice at the Veterans

Affairs Medical Center in Palo Alto, CA.

Her research interests include hepatitis,

electronic prescribing, and quality of life

evaluations. She began her career as a

prescribing pharmacist in the community

hospital setting, followed by several years on

the clinical faculty of the School of Pharmacy

at UC San Francisco, where she was respon-

sible for formulary management and guideline

development.

Dr. Devine is a fellow of the American

Society of Health-System Pharmacists and is

a board-certified pharmacotherapist specialist.

She is a member of the American Association

of Colleges of Pharmacy, the American

College of Clinical Pharmacy, the Academy of

Managed Care Pharmacy, the Drug Informa-

tion Association, and the International Society

for Pharmacoeconomics and Outcomes

Research. Dr. Devine was active for several

years with the California Society of Health-

System Pharmacists, serving both as board

member and presidential officer. During this

time, she supported legislation advancing

collaborative drug therapy management for

pharmacists. She serves on the executive

committee of the Section of Clinical Special-

ists of the American Society of Health-System

Pharmacists, where her efforts are in strength-

ening the role of the pharmacist in research.

Affiliate ProfessorMalcolm Maclure, ScD

Although Malcolm Maclure’s faculty

appointment to PORPP began very

recently (Spring 2002), he has a long

history with PORPP, having worked with

Dr. Stergachis, and more recently, with

Dr. Hazlet on the project evaluating

“Reference Pricing in British Columbia.”

Dr. Maclure received his BA in Biochem-

istry at Oxford and an MS and ScD in

Epidemiology from the Harvard School

of Public Health. He will collaborate

from his home position as Professor in

the School of Health Information Science

at the University of Victoria, British

Columbia. He has just been recognized as

a five-year Michael Smith Foundation for

Health Research Distinguished Scholar.

Dr. Maclure brings to PORPP his world-

renowned expertise in epidemiology and

extensive experience in working with

large-linked data sets. He will be

collaborating on projects and participat-

ing in classes and seminars. PORPP is

delighted to welcome him!

27

and

Pharmacogenomics

D avid Veenstra decided to pursue a career in pharmacoeconomics and outcomes

research toward the end of his graduate training at UC San Francisco. “I was

looking for a field that combined clinical evaluation and quantitative analysis,” he

recalls. “I was finishing my PhD in computational chemistry at the same time as

my PharmD, and pharmacoeconomics was the perfect fit.” He was offered a UW

postdoctoral fellowship, and headed to Seattle for formal training in the field. “I’ll

never forget—packing my stuff onto my motorcycle and riding up to Seattle. It was

like a whole new world opening up.”

Once at the UW, he quickly focused his efforts on cost-effectiveness modeling.

“I enjoyed the protein modeling and simulation work I had done during my PhD

training, and it was nice to transfer some of those skills to the clinical arena.” He

conducted research in technology assessment—in particular, evaluating novel

catheters designed to decrease the incidence of hospital-acquired infections. The

second year of his fellowship was spent with Roche Global Pharmacoeconomics in

Palo Alto, California. There, he learned more about the drug development process

and the role that pharmacoeconomics can play both in strategic decision making

in drug development and post-approval marketing. “I had a great opportunity to

be a member of several drug development teams,” an experience he says has been

invaluable. “It is difficult to understand the complexity of drug development

without participating in it directly. I think I had previously underestimated the

scientific challenges—and certainly the economic and political ones.”

After completing his postdoctoral training, Dr. Veenstra was offered a faculty

position with the UW, and decided to head back to Seattle. “That poor motorcycle.

I wore out yet another set of tires!” His objective was to pursue outcomes research

in the exciting new area termed ‘pharmacogenomics’—the use of genetic informa-

tion to guide individualized drug therapy. “Previously, I had studied the influence

of amino acid mutations on protein structure and stability. The thought of

evaluating the impact of genetic variants on clinical and economic outcomes was

just incredibly exciting.” Working in collaboration with his graduate student, Mitch

Higashi, and Dr. Kathryn Phillips of UC San Francisco, Dr. Veenstra developed a

cost-effectiveness framework for evaluating pharmacogenomic technologies. “We

published a paper directed toward the basic scientists in the field of pharmaco-

genomics, and the response has been tremendous. Clearly, there are a number of

important clinical, genetic, and economic issues that need to be sorted out quickly.

I think pharmacogenomic technologies will be coming to the market sooner than

most people realize.” He acknowledges that any paradigm shifts are decades away.

His most recent work was an evaluation of the risk of adverse outcomes in

patients taking warfarin (an anticoagulant) in relation to genetic variations in a

drug-metabolizing enzyme. CYP2C9 is a P450 enzyme that is responsible for the

primary metabolism of warfarin. About 30% of patients have at least one mutation

that prevents the proper metabolism of warfarin, theoretically putting these

patients at risk for bleeding events. Dr. Veenstra and his colleagues found that

patients with certain genetic variants were two times more likely to have a serious

or life-threatening bleeding event. “Is CYP2C9 genotyping cost effective? Well,

that’s exactly the next question we are attempting to answer. I think there will be a

lot of patients and clinicians out there wondering if they should be testing.”

Clearly, his work is relevant to many disciplines. Both as a PORPP faculty member,

and as a faculty member of the UW Institute for Public Health Genetics of the

School of Public Health and Community Medicine, Dr. Veenstra’s work will serve

to inform policies of the future.

27

facult y focusd a v i d v e e n s t r a

28

Nathorn Chaiyakunapruk, PharmD, PhD

Instructor, Department of Pharmacy Practice,

School of Pharmacy, Naresuan University

Dr. Chaiyakunapruk joined the PORPP

Graduate Program in 1997, with a PharmD

from the University of Wisconsin, and a BS in

Pharmacy from Chulalongkorn University,

Bangkok, Thailand. He received his PhD in

Pharmaceutical Outcomes at UW in Decem-

ber 2001, and has now returned to Thailand

where he is on the faculty at Naresuan

University. His dissertation was entitled,

“Meta-analysis and cost-effectiveness of

chlorhexidine gluconate and povidone iodine

In June 2001, PORPP graduated its first official “class” of masters and doctoral students. Among the graduates

were Nathorn Chaiyakunapruk, Mitchell K. Higashi, and Todd A. Lee, the first PhD students admitted into

our program in its inaugural year of 1997. The program’s first recipient of the combined PharmD-MS degree,

Holly Carlton Trautman, also graduated in 2001. All four have eagerly begun their new careers in academia or

industry. The PORPP faculty, students, and staff are extremely proud of our graduates.

New Alumni

use for the prevention of catheter-related

bloodstream infection.” His research interests

include technology assessment, systematic

reviews, and economic evaluation of phar-

maceuticals and services, particularly in the

areas of infectious disease, tropical medicine,

cardiovascular disease, and diabetes. He is

involved with a project, “Unmet need for drug

therapy in hospital visited patients,” funded

by Thai Health System Research Institute.

This project will use a large computerized

patient database to determine the magnitude

of inequity in receiving medications and

potential causes of problems.

PhD, PharmD-MS

29

Mitchell K. Higashi, MBA, PhD

Health Outcomes Scientist, GlaxoSmithKline

Dr. Higashi earned a PhD from PORPP

in 2001, an MBA from Eastern University,

Pennsylvania (1994), and a Bachelor’s degree

in Genetics, University of British Columbia,

Canada (1991). Dr. Higashi has held

positions in industry for Covance (Clinical

Research Associate) and Cardiome Pharma

(Director of Clinical Development). He

is now employed as a Health Outcomes

Scientist for GlaxoSmithKline.

Todd A. Lee, PharmD, PhD

Research Scientist, Hines VA Hospital

Research Assistant Professor,

Northwestern University

Adjunct Assistant Professor,

University of Illinois, Chicago

Dr. Lee earned a PhD from PORPP in 2001

and a PharmD from Drake University. He

is a senior investigator in the Midwest Center

for Health Services and Policy Research

(MCHSPR) housed at the Hines VA Hospital,

which is one of 13 VA Centers of Excellence.

He holds academic appointments in the

Center for Healthcare Studies in the North-

western University Feinberg School of

Medicine and the Department of Pharmacy

at the University of Illinois at Chicago. Prior

to joining MCHSPR, Dr. Lee was a managed

care fellow with Regence Blue Shield and

Premera Blue Cross in Washington state. He

also worked as a home care pharmacist. He is

working on several projects related to chronic

obstructive pulmonary disease (COPD) and

has published papers relating to the health

economics of asthma, COPD, and HIV.

Dr. Lee’s primary research focus is on patient

outcomes as they relate to the use of

pharmaceuticals, with a particular emphasis

on economic evaluation. Other research

interests include the use of economic

information in decision-making, evaluation

of quality of life, and cost-effectiveness

analyses in conjunction with clinical trials.

David Smith, RPh, MHA, PhD

Affiliate Assistant Professor

Research Scientist, Kaiser Center for

Health Research

Dr. David Smith was PORPP’s first graduate

from the PhD program. He earned his MHA

in 1995, and his PhD in Pharmaceutical

Outcomes in 1998, both from the University

of Washington. Following a two-year post-

doctoral fellowship at the University of York,

Dr. Smith is now developing his research

program at the Kaiser Center for Health

Research in Portland, Oregon. He is also an

affiliate faculty member of the PORPP

program.

Holly C. Trautman, PharmD, MS

Director of Pharmacy,

Community Health Plan of Washington

In 2001, Dr. Trautman became the first

recipient of the combined PharmD-MS

degree from PORPP. She earned a BA in

Medical Anthropology at Hampshire College

in Amherst, Massachusetts. She completed

a managed care fellowship while enrolled in

the PORPP program. She has worked as a

clinical pharmacist in diverse settings,

including home infusion, long-term care,

inpatient, outpatient, and managed care. As

Director of Pharmacy of Community Health

Plan of Washington, she is responsible for

formulary and clinical program develop-

ment, provider and member education and

outreach, academic programs, pharmacy

financials, and operations.

t

29

he training

I received at the

UW in PORPP

prepared me for all

facets of my day-

to-day work. The

didactic material

in the program

and the hands-on

research experi-

ence are invaluable

in handling issues

related to study

design or analysis

that I am con-

fronted with on a

daily basis.

—Todd Lee

Graduation 2001 (l to r):

Drs. Todd Lee, Mitch Higashi, Nathorn

Chaiyakunapruk, and Holly Trautman

30

In April 2001, the School of Pharmacy completed its 10-year Program

Review. The review committee consisted of reviewers both internal

and external to UW. The reviewers proclaimed the UW School of

Pharmacy to be a thriving center for excellence in research and

education. Due to its relative newness (1995), there was a specific

focus during the review on the PORPP program. The reviewers

commented on the sound foundation of the PORPP program, with

its strong leadership, excellent faculty, and notable student achieve-

ments. The committee indicated that PORPP has many of the

hallmarks of a thriving new educational enterprise. The reviewers

further commented on the ongoing collaborative work between

PORPP researchers and those at Fred Hutchinson Cancer Research

Center, the School of Public Health and Community Medicine, and

colleagues in the departments of pharmaceutics and medicinal

chemistry. Positive comments were also made about PORPP’s

curriculum.

In closing, the reviewers encouraged PORPP to augment

recruiting and expansion plans—a strong statement of encourage-

ment to those involved with the program!

Graduate Program Review

PORPP Welcomes Visiting Scholars

Andrew Street, PhD

On April 22, 2002, PORPP welcomed visiting scholar, Dr. Andrew

(Andy) Street to the UW campus. Dr. Street joins us from the

University of York, Center for Health Economics, where he is a Senior

Research Fellow. During his tenure at the UW campus, Dr. Street will

collaborate with PORPP faculty and students on research projects of

mutual interest, and participate in the weekly PORPP Seminar. His

tenure will extend to August 30, 2002. We look forward to working

with Dr. Street, and to further strengthening our bond with colleagues

at the University of York. Dr. Street was welcomed with a Departmen-

tal picnic, held in his honor.

Peter Smith, PhD

In 2000, Dr. Peter Smith joined us as a visiting scholar from the

University of York where he is Professor of Economics, Centre for

Health Economics. He has a joint appointment with the Department

of Economics and Related Studies, also at York. Dr. Smith is a mathe-

matics graduate of the University of Oxford. His research areas include

resource allocation, performance management, and productivity

analysis, both in the health care sector and in the broader public sector.

Visiting Scholars

Dr. Andy Street at spring picnic

31

Graduate Employment where they are now

MPH/MHA Managed Care ProgramsBrian Harris, MPH, 1988 Director of Pharmacy, Group Health Cooperative

Steve Hall, MPH, MHA, 1990 Account Manager Sanofi-Synthelabo

Linda Sturm, MPH, 1991 Associate Pharmacy Director, The Regence Group

Debbie Atherly, MPH, 1991 Student, UW/PORPP PhD Program

John Watkins, MPH, 1991 Formulary Director, Premera Blue Cross

David Hale, MHA, 1992 Intermountain Health Care, Salt Lake City, Utah

David Smith, RPh, MHA, 1995 Research Scientist, Kaiser Center for Health Research, Portland, Oregon

Joe Fazio, MPH, 1996 Northwest Pharmacy Services

Jennifer Hrachovec, MPH, 2001 Product Evaluator, Group Health Cooperative

Post-PharmD FellowshipsMary Helen Tran, PharmD, MBA, 1994 Senior Manager, Outcomes Research, Pfizer, Inc.

Libby Black, PharmD, 1995 Health Outcomes Manager, GlaxoSmithKline

Carmelina Battista, PharmD, 1996 Project Manager, MEDTAP International

Scott Strassels, PharmD, 1997 Student, UW/PORPP PhD Program

Dell Mather, PharmD, 1998 Prime Therapeutics

Welyn Chua Bui, PharmD, 1999 Senior Health Outcomes Research Consultant,

Lilly USA Health Outcomes Group

Essy Mozaffari, PharmD, 1995 Manager, Health Economics, Pharmacia

Reinee Sheffield, PharmD, 1997 Global Health Outcomes, Pharmacia

Darren Augenstein, PharmD, MBA, 1998 Pharmacist, Bartell Drugs

David Veenstra, PharmD, PhD, 1999 Assistant Professor, UW/PORPP Faculty

Doris Lew, PharmD, 2000 Kaiser Permanente, Oakland, CA

Beth Devine, PharmD, MBA, 2001 Research Assistant Professor, UW/PORPP Faculty

Post-PhD FellowshipsBJ Park, MD, PhD, 1993 Professor, Seoul University

Dan Malone, PhD, 1994 Associate Professor, Department of Pharmacy, Practice, and Science,

University of Arizona

Vlad Romano, MD, 1996 Faculty of Medicine, University of Romania

Olaf Klungel, PhD, 1999 Assistant Professor, University of Utrecht

Shelby D. Reed, PhD, 2000 Assistant Professor, Duke University, Clinical Health Policy Research

David Smith, RPh, MHA, PhD, 2000 Research, Scientist, Kaiser Center for Health Research, Portland, Oregon

Doctor of Philosophy, Pharmaceutical Outcomes

David Smith, RPh, MHA, PhD, 1998 Research Scientist, Kaiser Center for Health Research, Portland, Oregon

Nathorn Chaiyakunapruk, PharmD, PhD, 2001 Instructor, Department of Pharmacy Practice, Naresuan University, Thailand

Mitchell Higashi, MBA, PhD, 2001 Health Outcomes Scientist, GlaxoSmithKline

Todd Lee, PharmD, PhD, 2001 Research Scientist, Midwest Center for Health Services and Policy Research

Master’s Degree, Pharmaceutical Outcomes

Donna Marshall, PharmD, MS, 1999 Pharmacy Consultant, Uniform Medical Plan, Washington State

Sunshine Sommers, PharmD, MS, 1999 Pharmaceutical Outcomes Evaluator, Group Health Cooperative

Holly Carlton Trautman, PharmD, MS, 2001 Director of Pharmacy, Community Health Plan of Washington

32

Selected PublicationsFaculty2002Association between CYP2C9 genetic variantsand anticoagulation-related outcomes duringwarfarin therapy. Higashi MK, Veenstra DL,Kondo ML, Wittkowsky AK, SrinouanprachanhSL, Farin F, Rettie A. JAMA 2002;287:1690-1698.

Chlorhexidine compared with povidone-iodinesolution for vascular catheter-site care: A meta-analysis. Chaiyakunapruk N, Veenstra DL,Lipsky BA, Saint S. Ann Intern Med 2002;136(11):792-801.

Economic analyses and clinical practice guide-lines: why not a match made in heaven? RamseySD. J Gen Intern Med 2002 Mar;17(3):235-7.

Economic analysis of vinorelbine plus cisplatinversus paclitaxel plus carboplatin for advancednon-small-cell lung cancer. Ramsey SD, Moin-pour CM, Lovato LC, Crowley JJ, Grevstad P,Presant CA, Rivkin SE, Kelly K, Gandara DR.J Natl Cancer Inst 2002 Feb 20;94(4):291-7.

Increasing incidence of serious hypoglycemiain insulin users. Johnson ES, Koepsell TD,Reiber G, Stergachis A, Platt R. J Clin Epidemiol2002;55 (3):53-259.

Lifetime cancer-attributable cost of care forlong-term survivors of colorectal cancer.Ramsey SD, Berry K, Etzioni R.Am J Gastroenterol 2002 Feb;97(2):440-445.

Managed care and the US health care system:A social exchange perspective. Grembowski D,Cook K, Patrick DL, Roussel A. Social Scienceand Medicine 2002;54(8):67-1180.

Prevalence of serious eosinophilia and inci-dence of Churg-Strauss syndrome in a cohortof asthma patients. Loughlin JE, Cole JA,Rothman KJ, Johnson ES. Annals of Allergy,Asthma & Immunology 2002;88:319-325.

Productivity and medical costs of diabetesin a large employer population. Ramsey S,Summers KH, Leong SA, Birnbaum HG,Kemner JE, Greenberg P. Diabetes Care 2002Jan;25(1):23-9.

Socioeconomic issues related to antibiotic use.Reed SD, Laxminarayan R, Black D, SullivanSD. Ann Pharmacotherapy 2002;36:148-154.

The efficacy and tolerability of venlafaxinecompared with selective serotonin reuptakeinhibitors and other antidepressants: A meta-analysis. Smith DH, Dempster C, Glanville J,Freemantle N, Anderson I. Br J Psychiatry2002;180:396-404.

The practicality and validity of directly elicitedand SF-36 derived health state preferences inpatients with low back pain. Hollingsworth W,Deyo RA, Sullivan SD, Emerson S, Gray D,Jarvik JG. Health Econ 2002;11(1):71-85.

2001A comparison of diabetic foot ulcer patientsmanaged in VHA and non-VHA settings.Reiber GE, Smith DG, Carter J, Fotieo G,Deery HG, Sangeorzan JA, Lavery L, Pugh J,Bettine PR, Assal JP, del Aguila M, Diehr P,Patrick DL, Boyko EJ. J Rehabil Res Dev2001;May/June 38(3):309-317.

Age-related macular degeneration: cost of ill-ness issues. O’Neill C, Jamison J, McCulloch D,Smith D. Drugs and Aging 2001;18(4):233-41.

Abuse of futility. Curtis JR, Patrick DL,Caldwell ES, Collier AC. Arch of Intern Med2001;161(1):28-30.

AMCP guidance for submission of clinical andeconomic evaluation data to support formularylisting in US health plans and pharmacybenefits management organizations. Sullivan SD,Lyles A, Luce B, Gricar J. J Managed CarePharmacy 2001; 7(4):272-282.

An analysis of the cost and outcomes of emer-gency contraception prescribed by a pharma-cist in Washington State. Marciante KD,Gardner JS, Veenstra DL, Sullivan SD.Am J Pub Health 2001;91(9):1443-1445.

Comparison of the effectiveness of inhalerdevices in asthma and chronic obstructivepulmonary disease: A systematic review of theliterature. Brocklebank D, Ram F, Wright J,Cates C, Davies L, Douglas G, Muers M, SmithDH, White J. Health Technol Assess 2001;5(26).

Coronary artery bypass grafting in NativeAmericans: A higher risk for death than otherethnic groups? Nallamothu BK, Saint S, RamseySD, Fendrick M. J Gen Int Med 2001 Aug;16(8):554-559.

Cost and cost effectiveness of universal screen-ing for hearing loss in newborns. Kezirian EJ,White KR, Yueh B, Sullivan SD. Otolaryngol,Head Neck Surg 2001;124:359-67.

Cost-effectiveness of mircrosatellite instabilityscreening as a method for detecting hereditarynonpolyposis colorectal cancer. Ramsey SD,Clarke L, Etzioni R, Higashi M, Berry K, Urban N.Ann Intern Med 2001:135:577-588.

Design and analytic considerations in deter-mining the cost-effectiveness of early inter-vention in asthma from a multinational clinicaltrial. Sullivan SD, Liljas B, Buxton M, Lamm CJ,et al. Controlled Clinical Trials 2001; 22:420-437.

Design issues for conducting cost-effectivenessanalysis alongside randomized trials. RamseySD, McIntosh M, Sullivan SD. Annu Rev PublicHealth 2001;22:129-41.

Discounting for health effects in cost benefitand cost effectiveness analysis. Gravelle H,Smith DH. Health Econ 2001Oct;10(7):587-99.

faculty & students

33

Economic analysis of lung volume reductionsurgery as part of the National EmphysemaTreatment Trial. NETT Research Group.Ramsey SD, Sullivan SD, Kaplan RM, WoodDE, Chiang YP. Annals of Thoracic Surgery2001Mar;71(3):995-1002.

Economic evaluation of aquatic exercise forpersons with osteoarthritis. Patrick DL,Ramsey S, Spencer A, Kinne S, Belza B,Topolski T. Medical Care 2001; 39(5):413-424.

Economic evaluation of systemic treatments ofcytomegalovirus retinitis in patients with AIDS.Lee TA, Sullivan SD, Veenstra DL, Ramsey SD,Stefer PJK, Malinverni R, Pleil AM, Williamson T.Pharmacoeconomics 2001:19(5 Pt 2):535-550.

Emergency Contraception CollaborativePrescribing Experience in Washington State.Sommers SD, Chaiyakunapruk N, Gardner JS,Winkler J. J Am Pharm Assoc 2001;41:1-7.

Evaluating the quality of dying and death.Patrick DL, Engelberg RA, Curtis JR. J PainSymptom Manage 2001;Sep;22(3):717-26.

Factors associated with benzodiazepine use.Gray SL, Eggen AE, Blough DK. J Am GeriatrSoc 2001;49:S59.

Global strategy for the diagnosis, management,and prevention of chronic obstructivepulmonary disease. Pauwels RA, Buist AS,Calverly PM, Jenkins CR, Hurd SS, for theGOLD Scientific Committee. Am J Respir CritCare Med 2001;163:1256-1276.

Improving end-of-life experience and care inthe community: A conceptual framework.Byock I, Norris K, Curtis JR, Patrick DL. J PainSymptom Manage 2001;Sep;22(3):759-72.

Increasing access to emergency contraceptionthrough community pharmacies: Lessons fromWashington State. Gardner JS, Hutchings J,Fuller TS, Downing D. Family PlanningPerspectives 2001;33:172-175.

Inpatient costs, length of stay, and mortalityfor cerebrovascular events in communityhospitals. Reed SD, Blough DK, Meyer K,Jarvik JG. Neurology 2001;24:305-14.

International development of the Quality ofLife in Depression Scale (QLDS). McKenna SP,Doward LC, Kohlmann T, Mercier C, Niero M,Paes M, Patrick D, Ramirez N, Thorsen H,Whalley D. J Affect Disord 2001;Mar 63(1-3):189-99.

Lack of gender differences and large intra-subject variability in cytochrome P450 activitymeasured by phenotyping with dextromethor-phan. McCune JS, Lindley C, Decker JL,

Williamson KM, Meadowcroft AM, Graff D,Sawyer WT, Blough DK, Pieper JA. J ClinPharmacol 2001;41:723-31.

Management strategies for ribavirin-inducedhemolytic anemia in the treatment of hepatitisC: clinical and economics implications. DevineEB, Kowdley KV, Veenstra DL, Sullivan SD.Value in Health 2001;4(5):376-84.

Medication compliance in elderly patientsreceiving home health services following hospi-tal discharge. Gray, SL, Mahoney, J, Blough DK.Ann Pharmacother 2001;35:539-45.

Multicenter epidemiologic and health servicesresearch on therapeutics in the HMO ResearchNetwork–Center for Education and Researchon Therapeutics (CERT). Platt R, Davis R,Finkelstein J, Go AS, Gurwitz JH, Roblin D,Soumerai S, Ross-Degnan D, Andrade S,Goodman MJ, Marinson B, Raebel MA, SmithDH, Ukcickas-Yood M, Chan A. Pharmaco-epidemiol Drug Saf 2001 Aug-Sep;10(5):373-7.

Parameter solicitation for planning cost effec-tiveness studies with dichotomous outcomes.McIntosh M, Ramsey SD, Berry K, Urban N.Health Econ 2001;10:53-66.

Patients at high risk of death after lung-volume-reduction surgery. National Emphy-sema Treatment Trial Research Group.New Engl J Med 2001;345:1075-1083.

Patterns of self-rated health in older adultsbefore and after sentinel events. Diehr P,Williamson J, Patrick DL, Bild DE, Burke GL.J Am Geriatr Soc 2001;49(1):36-44.

Pharmacoeconomic impact of HMG-CoAreductase inhibitors in type 2 diabetes. Chai-yakunapruk N, Boudreau D, and Ramsey SD.J of Cardiovascular Risk 2001;8(3):127-132.

Probabilities of transition among health statesfor older adults. Diehr P, Patrick DL (2001).Qual Life Res 2001;10(5):431-42.

Quality of life and health-risk behaviors amongadolescents. Topolski TD, Patrick DL, EdwardsTC, Huebner CE, Connell FA, Mount KK.J Adolesc Health 2001;Dec 29(6):426-35.

Quality of life outcomes in the evaluation ofhead and neck cancer treatments. Schwartz S,Patrick D, Yueh Bevan. Arch Otolaryngol HeadNeck Surg 2001;June 127(6):673-78.

Randomized phase III trial of paclitaxel pluscarboplatin versus vinorelbine plus cisplatin inthe treatment of patients with advanced non-small-cell lung cancer: A Southwest OncologyGroup Trial. Kelly K, Crowley J, Bunn PA,Presane CA, Grevstad PK, Moinpour CM,

Ramsey SD, Wozniak AJ, Weiss GR, Moore DF,Israel VK, Livingston RB, Gandara DR.J Clin Oncol 2001;19(13):3210-3218.

Randomized trial of amplification strategies.Yueh B, Souza P, McDowell J, Sarubbi M, LoovisC, Hedrick S, Ramsey S, Deyo R. Arch Oto-laryngol Head Neck Surg 2001;127:1197-1204.

Recall bias in a prospective cohort study ofacute time-varying exposures: example fromthe herpetic eye disease study. Kip KE, Cohen F,Cole SR, Wilhelmus KR, Patrick DL, Blair RC,Beck RW. J Clin Epidemiol 2001;54(5):482-7.

Relative impact of patient and clinic factors oncompliance with primary care preventiveservices: An exploratory study. Ramsey SD,Cheadle AD, Neighbor WE, Gore E, Temple P,Staiger T, Goldberg HI. Medical Care 2001Sep;39(9):979-89.

Seattle 5-day worksite program to increasefruit and vegetable consumption. Beresford SA,Thompson B, Feng Z, Christianson A, McLerranD, Patrick DL. J Prev Med 2001:32(3):230-238.

The cost of liver transplantation for Medicarerecipients. Best JB, Veenstra DL, Geppert J,Lake J. Liver Transplantation 2001;7:858-862.

The costs of treating chronic obstructive pul-monary disease in the United States. StrasselsSA, Smith DH, Sullivan SD, Mahajan PS.Chest 2001;119:344-352.

The evolution and role of the online pharmacy.Stergachis A. P & T 2001;26:628-32.

The family conference as a focus to improvecommunication about end-of-life care in theintensive care unit: opportunities for improve-ment. Curtis JR, Patrick DL, Shannon SE,Treece PD, Engelberg RA, Rubenfeld GD. CritCare Med 2001Feb;29(2 Suppl):N26-33.

The health economics of asthma and allergicrhinitis: Part I. Assessing the economic impact.Weiss KB and Sullivan SD. J Allergy ClinImmunol 2001;107(1):3-8.

The health economics of asthma and allergicrhinitis: Part II. Sullivan SD and Weiss KB.J Allergy Clin Immunol 2001;107(2):203–210.

The impact of improved glycemic control onhealth care costs and utilization. Wagner EH,Sandhu N, Grothaus LC, Newton K, McCullochDK, Ramsey SD. JAMA 2001;285:182-89.

The impact of including future medical carecosts when estimating the costs attributableto a disease: A colorectal cancer case study.Etzioni R, Ramsey SD, Berry K, Brown M.Health Econ 2001 Apr;10(3):245-56.

34

The potential role of pharmacogenomics inpreventing adverse drug reactions: A syste-matic review. Phillips K, Veenstra DL, Oren E,Lee JK, Sadee WS. JAMA 2001;286:2270-2279.

The practice of discounting in economic eval-uation of health care interventions. Smith DH,Gravelle H. International J Health Technol Assess2001;17(2).

The role of hospital volume in coronary arterybypass grafting: is more always better? Nalla-mothu BK, Saint S, Ramsey SD, Hofer TP,Vijan S, Eagle KA. Journal of the AmericanCollege of Cardiology 2001;38(7):1923-30.

Transforming self-rated health and the SF-36scales to include death and improve interpret-ability. Diehr P, Patrick DL, Spertus J, Kiefe CI,McDonell M, Fihn SD. Medical Care 2001;39(7):670-680.

Treatment with tissue plasminogen activatorand inpatient mortality rates for patients withischemic stroke treated in community hospitals.Reed SD, Cramer SC, Blough DK, Meyer K,Jarvik JG. Stroke 2001;32:1832-40.

Use of alternative therapies by older adultswith osteoarthritis. Ramsey SD, Spencer AC,Topolski T, Belza B, Patrick DL. Arthritis andRheumatism 2001;June 45(3):222-227.

Washington State Alliance to Reduce PrescriptionDrug Spending: The “AWARDS” Program. Pre-pared for the Coalition for Affordable Prescrip-tions for Seniors. Sullivan SD, Kreling DH. 2001.

Weighted health status in the medicare popula-tion: Development of the Weighted HealthIndex for the Medicare Current BeneficiarySurvey (WHIMCBS). Doctor JN, Chan L,MacLehose RF, Patrick DL. Journal ofOutcome Measurement 2001;4(4):721-39.

2000A physician survey of the effect of drug sampleavailability on physicians’ behavior. Chew LD,O’Young TS, Hazlet TK, Bradley KA, MaynardC, Lessler DS. J Gen Intern Med 2000;15(7):478-483.

Antibiotics and clostridium difficile diarrhea inthe ambulatory setting. Levy DG, Stergachis A,McFarland LV, VanVorst K, Graham DJ,Johnson ES, Park BJ, Shatin DB, Clouse JC,Elmer GW. Clinical Therapeutics 2000;22:91-102.

Assessing the cost-effectiveness of pharmaco-genomics. Veenstra DL, Higashi MK, PhillipsKA. Pharmaceutical-Sciences 2000(Sept.14);2(3):Article 29.

Cost-benefit analysis of a clinical pharmacist’spresence on a post-liver transplant service.

Brethauer B, Devine EB, Jue M, Quan D, LouieC. Hospital Pharmacy 2000;35(11):1197-1202.

Direct medical costs of chronic obstructivepulmonary disease: chronic bronchitis andemphysema. Wilson L, Devine, EB, So K.Respir Med 2000;94;204-213.

Frequency and characteristics of cognitiveservices provided in response to a financialincentive. Christensen DB, Neil N, Fassett WE,Smith DH, Holmes G, Stergachis A.J Am Pharm Assoc 2000;40:609-17.

Incidence of adverse esophageal and gastricevents in alendronate users. Park BJ, Clouse J,Wysowski D, Shatin D, Stergachis A. J Phar-maco-epi and Drug Safety 2000;9:371-76.

Influence of a financial incentive on cognitiveservices: CARE Project Design/Implementa-tion. Christensen DB, Holmes G, Fassett WE,Neil N, Andrilla CH, Smith DH, Andrews A,Bell EJ, Hansen RW, Shafer R, Stergachis A.J Am Pharm Assoc 2000;40:629-39.

Measuring appropriate use of acute beds:A systematic review of methods and results.McDonagh MS, Smith DH, Goddard M.Health Policy, 2000 53. P 157-184.

Removal of drug samples from two teachinginstitutions [letter]. O’Young T, Hazlet TK.Am J Health Syst Pharm 2000;57(12):1179-1180.

Survey of Pharmacy Benefits. Prepared forWashington State Office of the InsuranceCommissioner. Hazlet TK, Bach M,Newcomer T. Spring 2000.

Tramadol and seizures: A surveillance studyin a managed care population. Gardner JS,Blough DK, Drinkard CR, Shatin D, AndersonGA, Graham D, Alderfer R. Pharmacotherapy2000; 20(12):1423-31.

Using generalized linear models to assessmedical care costs. Blough DK, Ramsey SD.Health Services and Outcomes Research

Methodology 2000;1:185-202.

Students2002Association between CYP2C9 genetic variantsand anticoagulation-related outcomes duringwarfarin therapy. Higashi MK, Veenstra DL,Kondo ML, Wittkowsky AK, SrinouanprachanhSL, Farin F, Rettie A. JAMA 2002;287:1690-1698.

Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care:A meta-analysis. Chaiyakunapruk N, VeenstraDL, Lipsky BA, Saint S. Ann Intern Med 2002;136(11):792-801.

The association between breast carcinoma andmeningioma in women. Custer BS, Koepsell TD,Mueller BA. Cancer 2002 Mar15;94(6):1626-35.

2001Assessing the cost-effectiveness of pharmaco-genomics. Veenstra DL, Higashi MK, PhillipsKA. AAPS Pharmsci 2001;2(3)1-11.

An economic evaluation of systemic treatmentsfor cytomegalovirus retinitis in AIDS patients.Lee TA, Sullivan SD, Veenstra DL, Ramsey SD,Steger PJK, Malinverni R, Pleil AM, WilliamsonT. Pharmacoeconomics 2001;19(5 Pt 2): 535-550.

Cost-effectiveness of microsatellite instabilityscreening as a method for detecting hereditarynonpolyposis colorectal cancer. Ramsey SD,Clarke L, Etzioni R, Higashi M, Berry K, UrbanN. Ann Intern Med 2001 135 577-588.

Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. MarcianteKD, Gardner JS, Veenstra DL, Sullivan SD. AmJ Public Health 2001 91 1443-1445.

Performance of community pharmacy drug inter-action software. Hazlet TK, Lee TA, Hansten PD,Horn JR. J Am Pharm Assoc 2001;41(2):200-4.

Pharmacoeconomic impact of HMG-CoAreductase inhibitors in Type 2 Diabetes.Chaiyakunapruk N, Boudreau D, Ramsey SD.J Cardiovasc Risk 2001;Jun;8(3):127-32.

The costs of treating COPD in the UnitedStates. Strassels SA, Smith DH, Sullivan SD,Mahajan PS. Chest 2001 119 344-352.

The emergency contraception collaborativeprescribing experience in Washington State.Sommers SD, Chaiyakunapruk N, Gardner J,Winkler J. J Am Pharm Assoc 2001;41:60-6.

2000Breast density as a predictor of mammographicdetection: comparison of interval- and screen-detected cancers. Mandelson MT, OestreicherN, Porter PL, White E, Finder CA. J NationalCancer Institute 2000; 92:1081-7.

Comparison of the efficacy and cost effectivenessof preemptive therapy as directed by CMV anti-genemia and prophylaxis with ganciclovir in lungtransplant recipients. Kelly J, Hurley D, Raghu G.J Heart Lung Transplant 2000Apr;19(4):355-359.

Hip abductor weakness in distance runners withiliotibial band syndrome. Fredericson M,Cookingham CL, Chaudbari AM, Dowdell BC,Oestreicher N, Sahrmann SA. Clin J Sports Med2000;10:169-75.

The economic burden of COPD. Sullivan SD,Ramsey SD, Lee TA. Chest 2000;117: 5S-9S.

35

Grants & GiftsThe accomplishments of the Pharmaceutical

Outcomes Research & Policy Program in 2000-

2002 would not have been possible without

generous educational grants and gifts provided

by our sponsors. We wish to express our sincere

gratitude to:

Abbott Laboratories

AstraZeneca

Aventis Pharmaceuticals

Bayer Corporation

Bristol-Myers Squibb

Centacor, Inc.

Eli Lilly and Co.

Genentech, Inc.

GlaxoSmithKline

Janssen Pharmaceuticals

Merck & Company, Inc.

Pfizer Pharmaceuticals

Novartis

Pharmacia

Procter & Gamble

Regence Blue Shield

Sanofi-Synthelabo

Schering Plough

Sepracor, Inc.

The Everett Clinic

Wyeth-Ayerst Labs

AffiliationsAcademy of Managed Care Pharmacy

Fred Hutchinson Cancer Research Center

Group Health Cooperative of Puget Sound

Health Care Financing Administration

Kaiser Northwest Center for Health Research

NDC Health Information Service

Premera Blue Cross

Program for the Appropriate Use of

Technology in Health (PATH)

Regence Blue Shield and The Regence Group

Roche Global Pharmacoeconomic Research

State of Washington Department of Social

and Health Services

United HealthCare Corporation

University of British Columbia, Canada

University of Utrecht, The Netherlands

University of York, United Kingdom

UW Center for Cost & Outcomes Research

UW Medical Center and

affiliated teaching institutions

VA Puget Sound Health Care System

Washington Dental Service

Washington State Pharmacy Association

t he Master’s

training in

pharmaceutical

outcomes research

incorporated

many of the skills

that I use on a

daily basis in my

current position.

The hands-on

training that was

offered at local

institutions

offered invaluable

experiences,

which I reflect

upon

frequently.

—Holly C.

Trautman

33

36

Department of Pharmacy

University of Washington

Box 357630

Seattle, WA 98195-7630

Phone: 206-616-4587

FAX: 206-543-3835

Email: porpp@u.washington.edu

http://depts.washington.edu/porpp

PHAR MAC E UTI CAL OUTC O M E S

RE S EARC H AN D PO LI CY PRO G R AM

PORPP AdministrationDirector

Sean D. Sullivan, PhD

sdsull@u.washington.edu

Associate Director

Emily Beth Devine, PharmD, MBA

bdevine@u.washington.edu

Director of Post-PharmD Fellowship Programs

David L. Veenstra, PharmD, PhD

veenstra@u.washington.edu

Program Operations Coordinator

Cynthia R. Bush

crbush@u.washington.edu

Program Coordinator

Penny L. Evans

pennye@u.washington.edu

Biennial Report TeamCynthia R. Bush

Emily Beth Devine

Penny L. Evans

Sean D. Sullivan

PhotosCindy Bush, Beth Devine, Penny Evans,

Tom Hazlet, Grace Lee, Mary Levin, UW Health SciencesCenter for Educational Resources, Kathy Sauber,

Cathy Schwartz, UW Photography

Design

Cathy Schwartz